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CHAPTER 1 
The human defense system against foreign agents or aberrant cells is 
comprised of both a humoral and a cellular response. The humoral re-
sponse consists mainly of the production of antibodies (Ab), that 
specifically recognize foreign antigens. Binding of Ab to antigens 
facilitates clearance of the antigen from the body by other cells of 
the immune system. These Ab are produced by B lymphocytes upon anti-
genic stimulation (humoral adaptive immunity). The cellular immune re-
sponse can be divided into a natural and an adaptive component. Natural 
immunity is provided by natural killer (NK) cells, granulocytes, and 
monocytesjmacrophages, which display their function without prior anti-
genic stimulation. NK cells are thought to provide a first line of 
defense against malignant or virus infected cells. Adaptive immunity is 
provided by T lymphocytes, which are activated by antigen-specific 
stimulation. Both NK cells and T lymphocytes can discriminate between 
self and non-self (foreign) cells. Cell mediated cytolysis of non-self 
cells is a major function of NK cells as well as cytotoxic T lympho-
cytes (CTL). The interaction between NK or CTL cells and non-self cells 
(target cells) resulting in target cell lysis, is a multistep process 
involving lymphocyte-target cell adhesion and, subsequently, lymphocyte 
activation. 
In this chapter the characteristics of distinct types of cytotoxic 
lymphocytes and the various steps of the cytolytic process will be 
discussed. 
Classification of cytotoxic lymphocytes 
At present three major subsets of cytotoxic lymphocytes can be dis-
tinguished by phenotypic features as their surface receptor(s) for 
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target cell recognition, the expression of other cell surface proteins, 
so-called cluster designation (CD) determinants, and the type(s) of 
cytolytic activity which they mediate (see below). These three subsets 
are: 1) T cell receptor (TCR) atr lymphocytes, 2) TCRyo+ lymphocytes, 
and 3) TCFl NK cells. The relevant distinguishing characteristics are 
summarized in Table 1.1. 
Table 1.1 Characteristics of cytotoxic lymphocyte subsets. 
Immunophenotype cytolytic activity 
Cloned 
lymphocyte CD3 CD4 CDS CD16 MHC- MHC-
subsets restricted unrestricted 
TCRa:l3+ + + + -(+a)) 
+ + + -(+a)) 
TCRyo+ + -(+b)) -/+ + + 
TCR- -(+d)) + + 
a) When cultured with a high dose of interleukin 2 (IL2). 
bl About 0-40%. 
cl When CD16 is expressed. 
d l About 30% of TCR- NK cells. 
ADCC 
-/+c) 
+ 
In this paragraph, the three types of cytotoxic lymphocytes will be 
discussed. TCRatr cells, which represent approximately 60-75% of per-
ipheral blood lymphocytes (PBL), express a disulphide linked hetero-
dimeric protein receptor for target cell antigen recognition. This re-
ceptor is composed of an « and a (3 chain of molecular weight (Mw) 40-45 
kDa each (1-3). Like immunoglobulins (Ig) (4), TCR« and (3 chains are 
encoded by genes constructed via rearrangement of multiple variable 
(V), joining (J), constant (C) and, in case of the (3 chain, also diver-
sity (D) region gene segments (5-8). The specificity of the TCR«(3 com-
plex for antigen is determined by the rearrangement patterns of TCR« 
and (3 genes (9). The TCR«f3 is noncovalently associated in a 1:1 ratio 
with the CD3 complex (see below). 
TCRyo+ cells represent approximately 0-10% of PBL (10-13). In mice, 
but not in humans, TCRyo+ lymphocytes are predominantly found in epi-
thelium of the skin (about 50% of the lymphocytes) (14,15) or intestine 
( 16, 17) • The TCRyo is composed of a y and o chain and similar to TCRatr 
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cells noncovalently associated with the CD3 complex (S,11,12,1S-22). 
Like TCRa and ~ chains, TCRy and o chains are encoded by V, J, c and 
D region gene segments. The human TCRy gene locus (21) contains two 
constant region genes Cy, of which Cy1, but not Cy2, encodes a highly 
conserved cysteine residue involved in the disulphide bridge between 
the y and o chain (23,24). This subdivides the TCRyo+ T lymphocytes 
into two subsets, based on the expression of a disulphide or a non-
disulphide linked heterodimer. 
The third subset of cytotoxic lymphocytes are the NK cells, which 
represent about 10% of PBL. NK cells do not express a TCR/CD3 complex 
(25,26). Their surface receptor for target cell recognition has not yet 
been identified (see below). 
The differential expression of other cell surface determinants (CD 
antigens) provides a second means 
subsets of cytotoxic lymphocytes. 
to distinguish among the three 
TCRcxt3" /CD3+ lymphocytes either 
express CD4 or CDS and lack cell surface expression of the Fe receptor 
(R)III for IgG (CD16). TCRyo+/CD3+ lymphocytes do not express CD4 and a 
small subset expresses CDS and/or CD16 (10,11,13,17,2S). TCR-/CD3- NK 
cells lack cell surface expression of CD4. They do express CD16 and 
about 30% of NK cells expresses CDS (29-32). 
Finally, the three cytotoxic lymphocyte subsets differ in types of 
cytotoxic activities displayed. The TCRcxt3" CTL specifically recognize 
foreign antigen in the context of proteins of the major histocompati-
bility complex (MHC) through the TCR~ complex (33,34). TCRcxt3" CTL can 
also recognize non-self MHC molecules. The specificity of TCRcxt3" CTL is 
reflected by their target cell spectrum; only those target cells that 
express the relevant combination of MHC determinant and antigen are 
recognized and subsequently lysed, a phenomenon referred to as 
MHC-restricted lysis. Coexpression of either cell surface CD4 or CDS 
correlates with restriction of lysis by MHC Class II or Class ·I mol-
ecules, respectively (reviewed in 35 and 36). Upon exposure to a high 
dose of interleukin 2 (IL2), some cloned TCRcxt3" CTL may, in addition to 
MHC-restricted lysis, also exert MHC-unrestricted lysis (37-39). 
Freshly isolated TCRyo+ CTL do not exert cytolytic activity. Their 
function in man is still unknown. In mice, the local accumulation .of 
TCRyo+ lymphocytes in epithelial tissue suggests an important barrier 
function against microorganisms ( 40). In humans, however, similar accu-
mulations have not been found. 
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Cloned TCRyo+ CTL display MHC-unrestricted lysis (10,11,41,42). 
Cloned TCRyo+ CTL from both mice and humans may also display antigen 
specific andjor MHC-restricted recognition (42-46). It is assumed that 
antigen recognition by TCRyo+ cells occurs via the TCRyo complex. The 
homology with the rearrangement patterns of TCR~ and ~ chain genes and 
Ig gene segments, suggests similar specificity for the TCRyo receptor. 
Thus, cloned TCRyo+ CTL may display both antigen specificjMHC-restric-
ted and MHC-unrestricted cytotoxic activity. This might be explained by 
assuming that there are two receptors: the TCRyo receptor involved in 
antigen-specificjMHC-restricted lysis and an unidentified receptor 
involved in MHC-unrestricted lysis. When expressed, CD16 (IgG receptor) 
enables cloned TCRyo+ CTL to lyse Ab-coated target cells, a phenomenon 
known as antibody dependent cellular cytotoxicity (ADCC) (10,11,13). 
NK cells do not express a TCR/CD3 complex and their lytic activity 
is MHC-unrestricted. In the past years several cell surface structures 
have proven to be critical in MHC-unrestricted lysis (38,47,48), but 
thus far there is no consensus on a common receptor. Instead, it is 
hypothesized that there is not just one receptor,. but that multiple 
receptors on NK cells are involved in target cell recognition (49,50). 
The target cell structure(s) recognized by NK cells have not been 
identified (47). However, the expression of so-called tumor associated 
antigens (~) on a number of tumors suggests that tumor cell recog-
nition occurs via these antigens. NK cells are also characterized by 
their ability to exert ADCC through expression of CD16 (29-32). 
NK cell or CTL mediated lysis of target cells 
NK cell or CTL mediated lysis is a multistep event. This process is 
initiated by antigen nonspecific formation of lymphocyte-target cell 
conjugates (51-54). Conjugates are stabilized by subsequent lymphocyte 
receptor-antigen interaction. Thereafter, the lytic mechanisms become 
activated, followed by delivery of the lethal hit and subsequent lysis 
of the target cell. once the lethal hit has been delivered, the 
lymphocyte dissociates from the target cell and may bind to a new one 
(recycling) (55). 
There is still controversy about the mechanism of target cell lysis. 
TWO major models have been proposed (56,57), one of which supposes a 
direct lysis of target cells through exocytosis of pore-forming mol-
ecules (perforin or cytolysin) from granules (Figure 1.1) (58,59). The 
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A 
NK cell Target cell 
&.~~~~ 
8 
CTL Target cell 
~~.i' • ----t>~e.i!'i. • ----{> · ~ 
a b 
~ e:;''if • ----{> 
c 
D undefined receptor 
2J undefined antigen 
B T cell receptor w~h 
§ C03 complex 
2lliJ antigen I MHC 
®~~ granules containing 
• • pore-forming molecules 
Figure 1.1 Target cell lysis by pore-forming molecules from NK cells 
(A} or CTL (B). 
For reasons of simplicity, only the lymphocyte receptors 
involved in target cell recognition are depicted here. 
Lymphocyte receptor-antigen interaction (a} induces the 
release of pore-forming molecules at the interface (b). 
Thereafter lymphocyte and target cell dissociate (c) and 
the target cell is lysed through binding of pore-forming 
molecules (d). 
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observations that in some cases degradation of the nuclear membrane 
(60) and DNA fragmentation (61) preceed destruction of the cytoplasmic 
membrane indicate a second lytic mechanism. Compatible with this notion 
is that CTL, and possibly NK cells, may kill target cells without re-
lease of perforin (62,63). It was therefore proposed that the effector 
cell induces metabolic changes within the target cell which in turn 
lead to its lysis (60,61,64) (Figure 1.2). It is likely that a cyto-
toxic cell can activate multiple lytic mechanisms which may collec-
tively lead to target cell destruction. 
llffllll> T cell receptor with 
f!!!J' CD3 complex 
2§ airtigen I MHC 
n undefined process leading to 
\... v selfdestruction 
Figure 1.2 CTL induce metabolic changes within the target cell leading 
to its lysis. 
TCR-antigen interaction (a) induces metabolic changes 
within the target cells (b). Thereafter, the CTL dis-
sociates from the target cell (c), while the target cell is 
lysed (d). 
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Adhesion and/or signal transducing molecules 
Inhibition of conjugate formation with monoclonal antibodies (mAb) 
directed against cell surface molecules on CTL and/or target cells have 
demonstrated the existence of various accessory molecules (65). Access-
ory molecules are operationally defined here as cell surface struc-
tures which mediate adhesion, transduce regulatory signals or both 
(listed in Table 1.2). Cell surface molecules that transduce signals 
Table 1.2 Accessory molecules on lymphocytes involved in cytotox-
icity. 
Lymphocyte subset 
Accessory TCR~ TCRyo+ TCR-
molecules CTL CTL NK 
CD2 + + + 
CD3 + + 
CD4 + 
CDS + unknown unknown 
CD11a/CD18 + + + 
CD16 +a) + 
CD28 + + 
CD45 + unknown + 
Tp103 + + 
a) when expressed. 
across the membrane are defined as activation molecules. Multivalent 
Ab-accessory molecule interactions generally activate lymphocytes, 
whereas mono- or bivalent interactions usually inhibit lymphocyte func-
tions. The valency of Ab-antigen interactions is increased by cross-
linking mAb by their IgG-Fc to FCyR expressed on target cells (Fig-
ure 1.3A). This interaction may activate the lytic mechanisms of the 
lymphocyte, resulting in target cell lysis (66-70). 
The functional involvement of the major accessory molecules in 
lymphocyte mediated lysis is detailed below. Successively, the bio-
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chemical features of the accessory molecules, their role in lymphocyte 
adhesion and finally their function in signal transduction, are de-
scribed. 
A 
:>> F~ Target 
B 
:; 
c 
Figure 1.3 Induction of cytotoxic activity with antibodies. 
Cytolysis Qf target cells by cytotoxic effector cells 
(Eff.) can be induced by A) single mAb directed against an 
activation site, crosslinked via its Fe to FcyR expressed 
on the target cell, B) chemically coupled bispecific Ab-
heteroconjugate, comprising a mAb directed against an acti-
vation site and a mAb against a target cell determinant, 
and C) bispecific quadroma derived mAb, obtained by somatic 
fusion of two hybridomas producing a mAb against an acti-
vation site and a target cell determinant, respectively. 
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CD3 complex 
The CD3 complex consists of five nonpolymorphic proteins y, o, €, 
and a homodimer ~ (71-73). The CD3 complex is noncovalently associated 
in a 1:1 ratio with either the TCRa$ or the TCRyo. TCR-antigen inter-
actions induce local accumulation of TCR molecules, and hence CD3, at 
the interaction site between lymphocyte and antigen presenting cell 
(74). It is thought that this accumulation induces signal transduction 
by CD3 (75). Crosslinking of anti-CD3 mAb mimics TCR-antigen inter-
actions by inducing accumulation of TCR/CD3 complexes, leading to 
T cell activation. In contrast, soluble (noncrosslinked) anti-TCR or 
anti-CD3 mAb restrict this accumulation which decreases the TCR-antigen 
interaction, and subsequently MHC-restricted lysis. However, soluble 
anti-CD3 mAb also block lysis induced via other activation sites such 
as C02 (see below). Thus, soluble anti-CD3 mAb may deliver a negative 
signal, which nonspecifically blocks transmembrane signaling via a 
number of other activation sites. 
CD2 is a transmembrane protein of 50 kDa. It is expressed on vir-
tually all thymocytes and mature TCR+ T and TCR- NK cells (35,76,77). 
Three distinct epitopes, Tl1.1, T11.2 and Tl1.3, have been identified 
on the CD2 molecule (78). The Tl1.1 epitope is associated with the 
sheep red blood cell binding site, whereas the T11.2 and T11.3 epitopes 
are not. 
CD2 mediates cell-cell adhesion through interaction with its natural 
ligand leucocyte function associated antigen-3 (LFA-3) (CD58) (79-82), 
which is expressed on all leucocytes and various other cells (77). The 
CD2jLFA-3 interaction participates in adhesion of cytotoxic lymphocytes 
and target cells, thymocytes to thymic epithelium (83) and resetting of 
human T lymphocytes with human or sheep erythrocytes (80,84-87). In 
addition to its adhesion function, CD2 acts as an activation site 
through which cytotoxicity can be induced by NK cells or CTL using 
anti-CD2 mAb (78,88-90). 
Although CD2 is expressed on all cytotoxic lymphocytes, the require-
ments for activation via CD2 are different for the three distinct 
lymphocyte subsets. A combination of two stimuli, provided by mAb 
against T11.1 + T11.3, or T11.2 + T11.3 (78,89,90), or by anti-T11.3 
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mAb plus phorbol myristate acetate (PMA) (91) induces proliferation or 
cytotoxicity in all three subsets. In addition, cloned TCRyS+, but not 
TCR~, lymphocytes can be activated via a single anti-CD2 (anti-Tll.l) 
mAb (88,92). In some, but not all, lymphocyte-target cell combinations, 
cytotoxicity by TCR- NK cell clones can also be induced by a single 
anti-CD2 mAb (88,92,93). 
Recent studies have shown that target cell LFA-3 costimulates TCR~ 
lymphocytes activated with antigen, phytohemagglutinin (PHA), or 
anti-CD2 mAb (85,94-97). Activation of TCR~ lymphocytes via CD2 is 
fUnctionally linked to CD3, since removal of the TCR/CD3 complex from 
the surface by anti-CD3 mAb (a process referred to as modulation) ren-
ders these lymphocytes refractory to activation via CD2 (78,98), and 
CD2 activation of TCRyS+ clones is blocked by anti-CD3 mAb (92). More-
over, stimulation of TCR~ lymphocytes with anti-Tll.2 + anti-Tll.3 
mAb causes phosphorylation of CD3 chains (99). Recently, it has been 
found that CD2 is not only fUnctionally, but also physically, associ-
ated with CD3 (100). In CD3- NK cells, the CD2 activation pathway is 
functionally linked to that of CD16 (93, A. Moretta, personal communi-
cation). 
LFA-1 ( CD1la/CD18) 
LFA-1 is a member of a subgroup of the leucocyte integrin family, 
which includes several proteins with adhesion-like functions (101,102). 
This subgroup contains three members which share a common ~ chain 
(CD18) noncovalently associated with one of the three ~chains, COlla 
(LFA-1), CDllb (CR3 or Mac-1) or COlle (pl50/95) (Table 1.3). LFA-1 is 
expressed on all leucocytes. 
Table 1.3 Members of the leucocyte integrin LFA-1 (~2) subgroup. 
Subunit Mw (kDa) CD Known ligands 
~ ~ 
LFA-1 180 95 CD1la/CD18 ICAM-1 I ICAM-2 
CR3 or Macl 165 95 CD11b/CD18 C3bi receptor 
pl50/95 150 95 CD1lc/CD18 C3bi receptor 
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Natural ligands for LFA-1 are the intercellular adhesion molecules 
ICAM-1 (CD54) and ICAM-2 (103-106). ICAM-1 is a 90 kDa, monomeric, 
membrane glycoprotein with homology to neural cell adhesion molecule 
(NCAM) and myelin-associated glycoprotein (MAG) (105,107,108). ICAM-1 
is also the receptor for the major Rhinovirus (109,110). 
The LFA-l/ICAM-1 interaction is involved in homotypic adhesion of B 
cells, T cells and myeloid cells (111), and adhesion of TCR~ 
lymphocytes to a variety of cell types, including endothelial cells 
(112-114). The latter interaction is thought to play a role in the 
normal process of lymphocyte homing (115,116) and in T cell infil-
tration into areas of inflammation (117). Inflammation results in the 
producton of cytokines such as tumor necrosis factor (TNF), inter-
leukin-1 (IL-l) and interferon-y (IFNy) (reviewed by Beutler (118)). 
Although ICAM-1 is normally present at only low levels on endothelial 
cells (112,119), these factors induce its expression and subsequently 
increase adhesion of lymphocytes to the endothelial tissue 
(112,119-121). 
Recent evidence suggests that the LFA-1/ICAM-1 interaction is also 
involved in regulation of T cell function. Anti-CD11a mAb enhances, 
whereas anti-CD18 mAb decreases, adhesion-independent T cell prolifer-
ation (induced by anti-CD3 mAb) (122,123). In mice, anti-COlla mAb 
enhance proliferation of preactivated Tor B lymphocytes (124,125). 
Moreover, the LFA-1/ICAM-1 interaction coactivates: a) lysis triggered 
via the TCR/CD3 complex of both TCR~ and TCRyo+ CTL (126,127 ,Chap-
ter 5), b) MHC-unrestricted lysis by TCR- NK cells or TCRyo+ CTL 
(126,128,Chapter 6), c) lysis triggered via the CD16 activation antigen 
expressed on TCR- NK cells (128,Chapter 6). 
CD16 
At present, three types of receptors for inmrunoglobulin IgG ( FcyR) 
have been identified: FcyRI, FcyRII, and FcyRIII (129-131) (Table 1.4). 
CD16 (FcyRIII) is expressed on TCR- NK cells, a small proportion of 
\TCRyo+ lymphocytes, neutrophils, eosinophils, tissue macrophages, and 
cultured monocytes (29,31,32,132,133). CD16 is a monomeric transmem-
brane protein of 50-70 kDa (129). NK cells and TCRyo+/CD16+ CTL lyse 
IgG-coated target cells through interaction with CD16 (ADCC) (29,31). 
Alternatively, anti-CD16 mAb can induce lysis of FcyR+ target cells 
(68). CD16 on NK cells is functionally linked to LFA-1 and C02 
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(88,93,128,134). CD16 on TCRyo+ cells is functionally linked to LFA-1 
and CD3, but not to C02 (126,128). Moreover, crosslinked anti-CD16 mAb 
induce lymphokine production (TNF,IFN-y,etc.) by NK cells (135,136). 
Table 1.4 Characteristics of human FcyR. 
Type of FcyR CD Mw (kDa) 
FcyRI 70 
FcyRII CDw 32 40 
FcyRIII CD16 55-70 
CD4/CD8 
Cell distribution 
monocytes, macrophages, 
neutrophils, myeloid cells 
B cells, monocytes, macro-
phages, eosinophils, 
neutrophils, myeloid cells 
monocytes, macrophages, 
neutrophils, eosinophils, 
NK cells, TCRyo+ CTL 
Both CD4 and CDS, which are generally expressed on mutually exclus-
ive TCR~ blood lymphocyte subsets, are involved in antigen non-
specific conjugate formation, because anti-CD4 or anti-COB mAb block 
lymphocyte-target cell adhesion (36). The target cell ligands for CD4 
or CDS molecules on the CTL are monomorphic determinants of MHC Class 
II or Class I molecules, respectively (137,138). These interactions 
increase the overall avidity between lymphocyte and target cells, 
thereby compensating a low affinity TCR-antigen interaction or lowering 
the requirement for high antigen density on target cells. 
In addition to their adhesion function, CD4 and CDS are also in-
volved in CTL activation after the formation of lymphocyte-target cell 
conjugates (139,140). Interaction of the TCR with its relevant MHC/ 
antigen induces the accumulation of both TCR/CD3 and CD4 (or CDS) at 
the interaction site (74,141). This physical association might alter 
the conformation of the TCR/CD3 complex. The formation of a quarternary 
complex consisting of MHC and antigen on the target cell, and TCR/CD3 
and CD4 (or CDS) on the lymphocyte is required for optimal lymphocyte 
activation (142,143). Whether CD4 (or CDS) initially associates with 
the TCR or the CD3 is presently unknown. The precise conformational 
changes in the TCR that lead to its association with CD4 (or CDS) is 
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also unknown. Soluble anti-CD4 or anti-CD8 mAb inhibit T lymphocyte 
activation possibly because they block coclustering of CD4 (or CDS) 
with the CD3/TCR (141,144,145). 
other accessory molecules 
Physiologic lymphocyte receptor-ligand interactions which lead to 
proliferation and/or lymphokine production or induction of target cell 
lysis can be mimicked by mAb. Thus the role of particular cell surface 
structures in these processes can be studied without knowing their 
natural ligand. This has revealed the existence of additional accessory 
molecules involved in the lytic cycle, such as CD28, Tp103 and CD45. 
CD28 (Tp44) is a disulphide-linked homodimer. It is expressed on the 
majority of TCR~ lymphocytes as well as TCRyo+ lymphocytes and 
thymocytes ( 146-148) • Anti-CD28 mAb have been shown to augment cyto-
lytic activity or proliferation triggered via either TCR/CD3 
indicating a functional linkage (147,149,150). However, 
or CD2, 
modulation 
experiments using anti-CD3 or anti-CD2 mAb demonstrated that CD28 is 
not physically linked to either the TCR/CD3 complex or C02 (151). 
Tp103 is expressed on in vitro cultured NK cells and CTL (152,153). 
Anti-Tpl03 mAb induced lysis by CTL clones, but not by NK cell clones 
(153, our unpublished observations). Modulation of the TCR/CD3 complex 
rendered cloned CTL refractory to activation by anti-Tp103 mAb. These 
data demonstrate that a functional TCR/CD3 complex is required for 
activation via Tp103 (153), probably because the Tp103 and CD3 sig-
naling pathways intracellularly converge to a common pathway. 
The CD45 antigen family consists of a series of high Mw proteins 
ranging in weight from 160-220 kDa expressed on all hemopoietic cells. 
Anti-CD45 mAb block lysis by NK or CTL cells (154,155). 
New mAb functionally reactive with structures on the lymphocyte 
membrane will undoubtedly reveal other accessory molecules involved in 
lymphocyte activation. However, the physiologic role of these acti-
vation signals largely remains to be defined. 
Induction of cytolysis by bispecific mAb 
Cytotoxic lymphocytes can be triggered to lyse IgG-FcR+ target 
cells, which are normally resistant to lysis, by using mAb which cross-
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link activation sites on the effector cell to FcyR on the target cell 
(Figure 1.3A). The use of bispecific mAb which can recognize two dis-
tinct antigens circumvents the requirement of FcyR on the target cell. 
Two types of bispecific Ab are currently used to crosslink lymphocytes 
and target cells. First, chemically coupled Ab-heteroconjugates, which 
comprise a mAb directed against an activation site on the effector cell 
crosslinked to a mAb directed against a target cell determinant 
(75,92,156,157) (Figure 1.3B). Crosslinked Fab or Fab2 fragments of mAb 
also produce functionally active Ab-heteroconjugates (126,128,156,158). 
Secondly, the so-called quadroma derived bispecific mAb, which are 
obtained by somatic fusion of two hybridomas producing mAb against 
lymphocyte activation sites and target cell structures, respectively 
(159-162). (Figure 1.3C). Bispecific mAb, comprising tumor cellspecific 
or virus-specific mAb may provide useful tools to enhance the elimin-
ation of tumor cells or virus infected cells in vivo (35,158,163,164). 
Clinical relevance and future prospects 
The ultimate objective of immunotherapy of cancer is eradication of 
tumor. This requires detailed knowledge of the immune network mechan-
isms. Despite the extensive information available on accessory mol-
ecules expressed on distinct lymphocyte subsets, as outlined in this 
general introduction, much is there to be learned. New accessory mol-
ecules on effector lymphocytes and ligands on target cells will be 
identified in the near future. Of particular interest will be to un-
ravel the complexity and nature of interactions between these accessory 
molecules on the one hand and their ligands on the other. Also, the 
effect of biological response modifiers such as interleukins, inter-
ferons etc. on the expression and function of accessory molecules needs 
to be further explored. The various signal transducing pathways and 
their relations to accessory molecules will further clarify their 
physiological role at the molecular level. 
Modulation of cytolytic activity by lymphocytes, in vitro as well as 
in vivo, will enable us to control and improve lymphocyte activation 
and eradicate tumor cells or viral infected cells. 
Thus, immunologic studies as reported in this thesis will contribute 
to the understanding of diseases caused by immunological defects as 
well as for the development of new immunotherapy strategies for the 
treatment of these diseases. 
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Objective of this study 
NK cells and subsets of CTL normally lyse target cells after signal 
transduction via particular surface receptor(s) for target cell recog-
nition. The cytotoxic activity of NK or CTL cells can be manipulated 
using mAb (either mono- or bispecific) directed against such lymphocyte 
receptors or against lymphocyte accessory molecules. 
The present study was initiated to determine 1) the requirements for 
selective in vitro generation and expansion of distinct cytotoxic 
lymphocyte subsets; 2) their proportions and cytotoxic capacities in 
tumor patients; 3) the requirements for activation of NK cells and CTL 
subsets via CD2, CD3 and CD16; and 4) the role of LFA-1/ICAM-1 inter-
actions in the cytolytic process. These in vitro studies provide infor-
mation relevant to the application of such cytotoxic lymphocytes and 
bispecific mAb in immunotherapy of cancer. 
In Chapter 2 culture conditions are described for selective in vitro 
generation and expansion of TCR~, TCRyo+ or TCR- NK cells. This al-
lowed to determine the proportions and cytolytic capacities of NK cells 
and CTL subsets derived from PBL and tumor infiltrating lymphocytes 
(TIL) (Chapter 3). It was found that the proportions of NK cells and 
CTL subsets with proliferative capacity in TIL was low as compared to 
PBL from either the same patients or from healthy donors. Those TIL 
with proliferative capacity in vitro, displayed cytotoxic activity 
comparable to that of PBL. 
The requirements for activation of NK cells or CTL via the acti-
tion sites CD2, 3 or 16 are described in Chapters 4, 5 and 6. In Chap-
ter 4 it is shown that in TCRyo+ CTL the requirements for activation 
via CD2 qualitatively differ from those in TCR~ CTL and TCR- NK 
cells. 
The role of accessory molecules and their ligands, in particular 
LFA-1/ICAM-1 interactions, was also studied (Chapters 5 and 6). The 
experiments described in Chapter 5 demonstrate that the LFA-1/ICAM-1 
interaction promotes CD3/TCR mediated lysis by CTL through: a) an 
enhanced CTL-target cell binding, and b) the delivery of postconjugate 
formation costimulatory signals. 
The functional importance of LFA-1/ICAM-1 interactions in lymphocyte 
activation, in particular 
described in Chapter 6. 
their role in MHC-~~restricted lysis, are 
It was found that LFA-1/ICAM-1 interactions 
also enhance MHC-unrestricted lysis by TCR"" NK cells as well as by 
TCRyo+ CTL. 
15 
Finally, the relevance of these 
protocols is discussed (Chapter 7). 
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CHAPTER 2 
I.EUCO!\GGLUTIN INDUCES DIFFERENTIAL PROLIFERATICN OF LYMPHOCYTE 
SUBSETS 
Introduction 
Functional, phenotypical and especially biochemical studies on 
lymphocyte subsets require large numbers of relatively pure cells. 
Lectin, antigen, monoclonal antibodies (mAb) and interleukin 2 (IL2) or 
combinations thereof, have proven to be efficient inducers of in vitro 
proliferation of lymphocytes (1-8). Study on the heterogeneity of 
lymphocytes requires nonselective expansion of distinct lymphocyte 
subsets. Nonselective culture systems for T cells using anti-CD3 mAb 
(2,4) or phytohemagglutinin (PHA) (5) have been described. In addition 
culture conditions have been described for the cloning of natural 
killer (NK) cells, using PHA plus IL2 (6,9,10), or irradiated Epstein 
Barr virus (EBV) transformed lymphoblastoid B cell lines (B-LCL) plus 
IL2 (6,7,10). 
We previously described a culture system that allows large scale and 
long-term expansion of major histocompatibility complex (MHC)-restric-
ted T cell receptor (TCR) otr/CD3+16- clones (8); MHC-unrestricted 
TCR-;co3-16+ NK clones (7) and the recently described TCRyo+;co3+16+ 
clones (11,12). This culture system is based on the use of a combi-
nation of two types of allogeneic irradiated feeder cells, i.e. periph-
eral blood lymphocytes (PBL) and EBV transformed B-LCL, plus leucoag-
glutinin. Here, we describe modifications of this culture system, i.e. 
at various concentrations of leucoagglutinin (range 0-1.0 pg/ml) selec-
tive expansion of TCR-/CD3- NK cells, (subsets of) T cells or unselec-
tive expansion occurs. Selective expansion of particular subsets of 
lymphocytes may be important for laboratory controlled cellular immu-
notherapy. Moreover, the availability of such culture systems allows 
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quantitative and qualitative analysis of lymphoid cell subsets derived 
from different (organ) sites. 
Materials and Methods 
Isolation of PBL 
PBL were isolated from healthy donors by centrifugation on Ficoll-
Isopaque (d=l.077 g/cm3 ) (Pharmacia Fine Chemicals, Uppsala, Sweden). 
The number of lymphocytes was determined by May-Grtinwald-Giemsa stain-
ing of cytospin preparations. PBL were either directly used, or cryo-
preserved into liquid nitrogen. 
Culture conditions 
PBL were cultured in round-bottomed 96 well microtiter plates 
(Greiner Labor Technik, Phidelsheim, FRG) in the presence of irradiated 
feeder cells (20 Gy). Two x 104 irradiated allogeneic PBL and 104 ir-
radiated EBV transformed lymphoblastoid B cell lines (B-LCL) were added 
to each well (8,13). RPM! 1640 (Flow Laboratories, UK) culture medium 
was buffered with 20 mM Hepes, supplemented with 10% pooled human 
serum, 4 mM glutamine, 1 pg/ml indomethacin, 100 IU/ml penicillin/ 
streptomycin and 5% v;v of IL2 containing supernatant from con-
canavalin-A activated PBL. The lectin leucoagglutinin (purified phyto-
hemagglutinin (PHA), HA-15 Pharmacia, Uppsala, Sweden) was added to the 
cultures at various concentrations (range 0-1.0 pg/ml). Plates were 
incubated at 37°C in 5% atmosphere of C02 • Lymphocytes were harvested 
and replated with new feeder cells in fresh medium at weekly intervals. 
Cloning and expansion of lymphocyte subsets 
Lymphocyte clones were generated by limiting dilution: PBL were 
plated at 1, 3, 10, 30, 100, 300, 1000 and 3000 cells per well to de-
termine the fraction of negative wells. The frequency of proliferating 
lymphocytes (plating eficiency) was calculated by the minimum X2 method 
from a Poisson distribution relationship between the logarithm of the 
percentage of negative wells and the cell number (14). Wells were 
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microscopically screened fer the presence of proliferating lymphocytes. 
Between day 12 and 14 proliferating lymphocytes were transferred into 
8-24 wells. Fresh medium plus feeder cells were added as described 
above. Lymphocytes were replated weekly. Proliferation of cloned and 
bulk cultured lymphocytes was analysed by cell counting and calculation 
of the multiplication factor. The multiplication per week of PBL cul-
tures was calculated by dividing the 7-day cell yield by the cell num-
ber at day 0. 
calculation of the doubling time and cumulative cell yield of cultured 
TCR+ /CD3+ 4+ and TCR+ /CD3+s+ lymphocytes 
The plating efficiency of a subpopulation of lymphocytes within 
bulkcultured PBL (here CD4 or CD8), was calculated using the Poisson 
formula and the plating eficiency of PBL from limiting dilution experi-
ments. The plating efficiency of co4+ or cos+ lymphocytes was used to 
calculate the doubling time of these lymphocyte subsets in bulk cultu-
res, using the formulas: 
% d XC 
in which Md = Multiplication factor of a single lymphocyte in bulk 
culture. 
C = CUmulative cell yield. 
%d =Percentage of a lymphocyte subset d (= TCR+/CD3+4+ or 
TCR+ /CD3+ a+ ) • 
N = Total number of lymphocytes plated. 
PEd = Plating efficiency of subset d. 
b = Number of cell divisions. 
T = Number of hours to obtain c. 
G = Doubling time in hours. 
Cell surface marker analysis 
Fresh, bulk cultured and cloned PBL were immunophenotyped using 
monoclonal antibodies (mAb): anti-CD3, wr32 (Dr. W. Tax, Nijmegen, The 
Netherlands), OKT4 and OKTS (Ortho Pharmaceutical, Raritan, NJ, USA), 
anti-CD25, Tac (Dr. T. Uchiyama, Kyoto, Japan), and anti-CD16 VD2 
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(CLB-FcR granl) (Dr. P.A.T. Tetteroo, Central Laboratory of The Nether-
lands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands) 
and B73.1 (15) (Dr. G. Trinchieri, Wistar Institute, Philadelphia, 
USA). The fluorescein isothiocyanate-conjugated goat anti-mouse IgG Ab 
was obtained from Nordic, Tilburg, The Netherlands. Lymphocytes were 
labeled with mAb as described elsewhere (8) and analysed with a fluor-
escence activated cell sorter (FACS II) (Becton Dickinson, Sunnyvale, 
California, USA). 
Results 
Leucoagglutinin increases the multiplication factor of PBL cultured in 
bulk 
PBL obtained from healthy donors were cultured for 3-4 weeks with 
1.0 pg/ml and without leucoagglutinin. High concentrations of leucoag-
glutinin (> 2 pg/ml) impaired optimal lymphocyte proliferation (data 
not shown). Without leucoagglutinin, the multiplication factor varied 
from 6 to 13 in the first week of culture among 4 donors tested 
(Table 2.1). 
However, in the presence of 1 pg/ml leucoagglutinin the number of 
PBL multiplied > 53 times. In both culture conditions the multipli-
cation factor obtained in the second week was significantly higher than 
in the first week of culture since 1) the number of responder lympho-
cytes was increased at the start of the second week and 2) there 'NaS a 
lag period preceding proliferation at the start of the first week of 
culture. Nevertheless, the cell yield obtained in leucoagglutinin 
stimulated cultures always exceeded that of non-leucoagglutinin stimu-
lated cultures by a factor 1.5-11. 
Leucoagglutinin in bulk cultures promotes the expansion of TCR+/CD3+16-
T cells over TCR-/CD3-16+ NK cells 
The proliferation enhancing effects of different doses of leucoag-
glutinin (range 0.1-1.0 pg/ml) on the lymphocyte subset composition of 
PBL was studied longitudinally. When PBL were cultured without leuco-
agglutinin, selective expansion of TCFl/CD3-16+ NK cells occurred in 
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Table 2.1 Leucoagglutinin increases the multiplication factor per 
week of bulk cultured PBL. 
Multiplication factor 
Experimental Donor Day 6 Day 12 
1 HD1646 
2 
HD1647 
HD1648 
HD1649 
0 
13 
8 
6 
9 
Leucoagglutinin 
1 
63 
53 
66 
75 
(pg/ml) 
0 1 
29 104 
27 101 
79 107 
149 324 
al Lymphocytes were directly cultured after isolation (3xl0 3 PBL per 
well in experiment 1) or frozen and thawed (lxl0 3 PBL per well in 
experiment 2). 
the first 2 weeks. Among 10 healthy donors, the initial percentage of 
CD16+ lymphocytes mean 16% (range 8-21%) increased to on average 49% 
(range 30-65%) at day 14. Consequently, the percentage CD3+ lymphocytes 
decreased from 65% (range 53-79%) to 45% (range 35-70%). A representa-
tive example is shown in Figure 2.1. The increase of the percentage 
TCR-/CD3-16+ NK cells during the second week resulted in a significant 
increase of the CD16+;cn3+ lymphocyte ratio from 0.30 to 2.0. There-
after the proportion of TCR-;cn3-16+ NK cells gradually decreased to 
less than 10% of the total lymphocyte population. 
In contrast, when 1 pg;ml leucoagglutinin was added to the cultures 
there was no percentual increase in TCR-/CD3-16+ NK cells. Instead, the 
proportion of TCR+;cn3+16- T cells rapidly increased to 95-100%, indi-
cating an almost complete overgrowth by TCR+;cn3+16- lymphocytes. 
Intermediate concentrations of leucoagglutinin induced proliferation of 
both subsets, until day 14. Thereafter, the proportion of cn3+ 
lymphocytes rapidly increased. 
When absolute numbers of TCBC/CD3-16+ lymphocytes were determined in 
cultures with and without leucoagglutinin higher numbers of 
TCR-;cn3-16+ NK cells were found in cultures with leucoagglutinin. 
Without leucoagglutinin on average a 1000±200-fold increase in 
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Figure 2.1 Rapid expansion of TCR+ /CD3+16- T lymphocytes in PBL bulk 
cultures in the presence of leucoagglutinin. 
PBL were cultured for 3 to 4 weeks with feeder cells and 
various concentrations leucoagglutinin as described in 
Materials and Methods. Lymphocytes were harvested at weekly 
intervals, and the percentage of CD3+ and CD16+ lymphocytes 
was determined by indirect immunofluorescence (flow cyto-
metry). A.= 0 ,ugjml; e = 0.1 ,ug/ml; T = 0.3 ,ug/ml; 1111 = 
1.0 ,ug/ml leucoagglutinin. 
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TCR-/CD3-16+ NK cells was obtained, resulting in an approximately 70% 
pure NK cell population at day 14. In contrast, with 1 ~g/ml leucoag-
glutinin, a > 2000±500-fold increase in TCR-/CD3-16+ NK cells was 
obtained at day 14, but the percentage NK cells was only s 6%. 
'l'he preferential outgrowth of TCR+/CD3+8+ over TCR+/CD3+4+ lymphocytes 
in bulk cultures is leucoagglutinin independent 
To assess the effect of leucoagglutinin on TCR+;co3+4+ and 
TCR+;co3+s+ T cell subsets in bulk cultures, we have calculated at 
weekly intervals the multiplication factor for both lymphocyte subpopu-
lations, and the CD4+ ;cos+ lymphocyte ratio in cultures with and with-
out leucoagglutinin. The multiplication of TCR+;co3+s+ lymphocytes 
under both culture conditions was about equal or exceeded that of 
TCR+;co3+4+ lymphocytes (Table 2.2) as reflected by the virtually lin-
ear decrease in the co4+;cos+ lymphocyte ratio (Figure 2.2). The in-
iial CD4+;coa+ ratio (2.0-3.3) decreased to below 0.5 after 3 weeks of 
culture. 
Table 2.2 Leucoagglutinin independent preferential proliferation of 
TCR+;co3+a+ lymphocytes. 
Multiplication factoral of 
CUlture period CD4+ cells cos+ cells 
in weeks 
Ob) 0.1 0.3 1.0 0 0.1 0.3 1.0 
lc) 18 58 228 281 35 92 246 288 
2 84 106 176 315 119 127 141 299 
3 81 74 126 421 100 134 491 761 
4 12d) 21d) 66 102 53d) 88 153 125 
a) See Materials and Methods for calculation of the multiplication 
factor. 
b) Concentration of leucoagglutinin (~g/ml). 
c) PBL of HD1649 were cultured at lxl0 3jWell. 
d) The number of responder cells plated was 2xl0 3jWell. 
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In order to investigate whether the 
TCR'" /CD3+ 16- or TCR- /CD3-16+ lymphocyte 
selective proliferation of 
(sub) populations in bulk cul-
tures with or without leucoagglutinin was influenced by the original 
PBL subset composition, lymphocytes were also cultured under limiting 
dilution conditions. 
i I I 
2 3 3 
period of culture (week) 
Figure 2.2 Leucoagglutinin independent outgrowth of TCR+/CD3+s+ lym-
phocytes in bulk cultures. 
PBL were cultured for 3 to 4 weeks with feeder cells and 
various concentrations leucoagglutinin as described in 
Materials and Methods. Lymphocytes were harvested at weekly 
intervals and the percentage of CD4+ and cos+ lymphocytes 
was determined by indirect immunofluorescence (flow cyto-
metry) and the CD4+ /CDS+ ratio was calculated. A= 0 pg/ml; 
e = 0 .1 pg/ml; 'V = 0. 3 pg/ml; 1111 ~ 1. 0 pg/ml leucoag-
glutinin. 
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Under limiting dilution leucoagglutinin increases the plating ef-
ficiency and life span of TCR+/CD3+4+ and TCR+/CD3+8+ clones 
Lymphocyte clones were generated with and without 1 pg/ml leucoag-
glutinin. After 13 days microtiter wells were microscopically screened 
for proliferation of lymphocytes to determine the plating efficiency. 
The fraction of "negative wells" (no proliferating lymphocytes) showed 
a logarithmic correlation with the number of cells seeded (Figure 2.3), 
indicating a "single hit" phenomenon, i.e. no influence of the cell 
culture composition on the plating efficiency of individual lympho-
cytes. The plating efficiency of resting PBL was less than 12% when 
cultured without leucoagglutinin, but in contrast more than 44% PBL 
proliferated in the presence of 1 pg/ml leucoagglutinin (Table 2.3). 
~landomly picked clones were further expanded for another (third) week 
to obtain sufficient cell numbers to allow immunophenotypic analysis. 
At the end of the third week only 50% of the clones still proliferated 
when no or 0.1 pg/ml leucoagglutinin was present in the medium. How-
ever, up to 90% still proliferated provided 1 pgjml leucoagglutinin was 
present (Table 2.4). 
Cells per well 
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Figure 2.3 Frequency of proliferating PBL of a healthy donor (HD 
1780). 
PBL were cultured under limiting dilution conditions. 
The number of lymphocytes plated was plotted against the 
log scale of the fraction of negative wells. The plating 
efficiency was calculated as indicated in Materials and 
Methods. 
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Table 2.3 Leucoagglutinin increases the plating efficiency of PBL in 
limiting dilution experiments. 
Experimenta l Donor Leucoagglutinin Plating efficiency 
(pg/ml) (%) 
1 HD1649 0 11 
2 HD1385 0 7 
3 HD1714 1.0 53 
4 HD1733 1.0 45 
5 HD1780 1.0 48 
a l Lymphocytes were frozen and thawed (experiment 1, 2 and 3) or di-
rectly cultured after isolation (experiment 4 and 5). 
Table 2.4 
2 
4 
Preferential outgrowth of TCR+;co3+4+ clones under limiting 
dilution conditions. 
Donor 
RD1649 
RD1649 
RD17l4 
RD1733 
RDl780 
Leuco-
agqlutinin 
(pg/ml) 
0.1 
1.0 
1.0 
l.O 
No. of clones 
expanded 
week 2 
55 
70 
40d) 
40 
40 
Percentage 
of prolifer-
::;~g3gtones 
44 
51 
100 
98 
88 
Number and 
phenotype 
8 (CD3+4+)c) 
l (CD3+8+) 
l (CD3_4_8_ 
18 (CD3+4+) 
2 (CD3+8+) 
2 (CD3+4-8-) 
ll (CD3+4+) 
4 (CD3+8+) 
2 (CD3+4-8-) 
ll (CD3+4+) 
3 (CD3+8+) 
l (CD3+4-8-) 
23 (CD3+4+) 
6 (CD3+8+) 
a l Lymphocytes were thawed (experiment 1 and 2) or directly cultured 
after isolation (experiment 3 and 4). 
bl Data expressed as percentage of the number of clones expanded at 
week 2. 
c) The phenotype of the clones is given in parenthesis. 
dl In experiment 2, 3 and 4, 40 clones were taken for expansion using a 
randomization table. 
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Immunophenotypic analysis of cloned lymphocytes generated with and 
without leucoagglutinin 
In limiting dilution either with or without leucoagglutinin about 
75% of the clones obtained was TCR+;co3+4+, 10-20% was TCR+;co3+s+; 
about 10% was TCR+ /C03+ 4- s- and only one TCR-;co3- 4- s- NK clone was 
obtained (Table 2.4) 
This contrasts the above described 
TCR+;co3+s+ lymphocytes in bulk cultures. 
doubling time of cloned versus 
TCR+;co3+s+ lymphocytes. 
bulk 
preferential outgrowth 
We therefore calculated 
cultured TCR+;co3+4+ 
of 
the 
and 
calculation of the doubling time of TCR+/CD3+4+ and TCR+/CD3+8+ lym-
phocytes in bulk cultures and after cloning 
In order 
TCR+ /C03+ g+ 
to calculate the doubling time of TCR+;co3+4+ and 
lymphocytes in PBL bulk cultures the frequency of actually 
Table 2.5 Reduced doubling time of bulk cultured cos+ lymphocytes 
compared to cloned cos+ lymphocytes. 
Cell yield x 106 
Donor Leucoagglutinin Pheno- Average Bulk 
pg/ml type per clone 
(day 20) (day 19) 
HD1649 CD4 1.9 (S)a) l.Ob) 
CDS o.s (1) 9.4 
HD1649 0.1 CD4 2.2 (lS) 2.0 
0.1 CDS 2.1 (2) 37.5 
HD1714 1.0 CD4 2.1 (11) ndc) 
1.0 CDS 3.6 (4) nd 
HD1780 1.0 CD4 1.3d) (23) 1.8 
1.0 CDS 1.2d) (6) 40.1 
a) The number of clones is given in parenthesis. 
b) See Materials and Methods for calculation. 
c) nd =not done. 
d) Cell yield at day 21. 
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Doubling time 
(h) 
Clones Bulk 
23.0 22.9 
24.6 19.7 
22.8 2l.S 
22.S 1S.l 
22.8 nd 
22.0 nd 
24.S 22.0 
24.9 1S.1 
triggered lymphocytes was determined. Since the plating efficiency 
determined in limiting dilution experiments was not influenced by 
cell-cell interactions, we used this plating efficiency also for bulk 
cultures (see Materials and Methods). The doubling times for cloned 
TCR+;co3+4+ and TCR+;co3+a+ lymphocytes varied from 22 to 25 h 
(Table 2.5). In bulk cultures also the doubling time of TCR+;co4+ 
lymphocytes varied from 22 to 24 h, but was much shorter for TCR+ ;cos+ 
lymphocytes, i.e. between 18 to 20 h. The shorter doubling time for 
TCR+;co3+a+ lymphocytes in bulk cultures as compared to cloned 
TCR+;co3+a+ lymphocytes was leucoagglutinin independent. These data 
indicate that TCR+;co3+4+ lymphocytes promote proliferation of preacti-
vated TCR+;co3+a+ lymphocytes, e.g. by production of lymphokines. 
Discussion 
Large scale in vitro expansion of lymphocyte subsets serves two 
important purposes. Firstly, analysis of immune cell interactions and 
biochemical as well as functional characterization of the cell surface 
molecules involved, require large numbers of cells. Secondly, it is of 
particular importance for these studies as well as for the design of 
immunotherapy protocols to be able to selectively expand distinct sub-
sets of immune cells. These two factors of the culture system, i.e. 
multiplication capacity and selective proliferation capacity are deter-
mined by the various components of the culture system, such as feeder 
cells, endogenous as well as exogenous cytokines, lectins and/or ~. 
We previously determined the number and type of irradiated EBV trans-
formed B-LCL and irradiated allogeneic PBL, and exogenous IL2 concen-
trations, optimal for the expansion of both NK cell derived clones and 
T cell derived clones (7,8,13). 
This report describes how the multiplication capacity and selective 
proliferation capacity of the culture system can be modified by chang-
ing the concentration of leucoagglutinin, allowing selective expansion 
of ~/CD3+16- T cells or TCR-;co3-16+ NK cells or the nonselective 
expansion of both subsets of lymphocytes. 
The multiplication factor of bulk cultured PBL gradually increased 
with the amount of leucoagglutinin added, reaching a plateau at 
1 pg;ml. This gradual increase of the multiplication factor is probably 
due to an increased fraction of lymphocytes triggered to proliferate, 
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as determined in limiting dilution experiments (Table 2.3). Similarly, 
Moretta et al. (5) observed a 4-5-fold increase in plating efficiency 
for PBL when PHA was added. 
Not only the multiplication factor but also the subset composition 
of bulk cultured PBL harvested at weekly intervals was markedly 
influenced by leucoagglutinin. In the presence of leucoagglutinin, the 
initial percentage TCR-/CD3-16+ NK cells (5-20%) declined within 2 
weeks to undetectable low levels, whereas the percentage TCR+;cn3+16- T 
lymphocytes increased to approximately 95. 
In contrast, cultures without leucoagglutinin contained about 70% 
pure TCR-/CD3-16+ NK cells after 2 weeks culture (Figure 2.1). This 
result is comparable with the observation of Perussia et al. (16), who 
obtained 50% TCR-;ao3-16+ NK cells among PBL cultured with irradiated 
Daudi cells at day 10. 
Although leucoagglutinin counteracts the selective proliferation of 
TCR-;ao3-16+ NK cells among PBL, higher absolute numbers of NK cells 
were obtained in the presence of 1 pg/ml leucoagglutinin: without 
leucoagglutinin an average 1000-fold increase of TCR-/CD3-16+ NK cells 
was obtained at day 13, but ~ 2000-folq increase was obtained in the 
presence of 1 pg/ml leucoagglutinin. These data suggest that in ad-
dition to TCR+;ao3+16- T lymphocytes leucoagglutinin also stimulates 
TCR-;ao3-16+ NK cells. This was also suggested by others (17,18), who 
observed that the number of IL2 receptors is increased on NK cell 
clones and LGL respectively upon stimulation with PHA. However, the 
proliferation stimulating effect of leucoagglutinin is much more pro-
nounced on TCR+/CD3+16- T lymphocytes as illustrated by the undetect-
able percentage of TCR-/CD3-16+ NK cells after 2 weeks of culture. 
The high multiplication factors reported here for TCR-;ao3-16+ NK 
cells exceeds those reported by others. For comparison: Perussia et al. 
(16) observed a 25-fold increase of TCR-;cn3-16+ NK cells in PBL at day 
13 cultured with irradiated Daudi cells as feeders; Talmadge et al. 
(17) obtained a 6-fold increase of Percell enriched LGL at day 13 in 
response to recombinant (rec) IL2 (500 U;ml); Phillips et al. (19) 
observed a preferential stimulation of sorted Leu 11a+ (anti-CD16 mAb) 
cells upon stimulation with K562 cells, optimal at day 5 of culture as 
determined by [ 3 H] thymidine incorporation; Ochoa et al. (20) observed 
a 30-100-fold increase of lymphocytes displaying LAK activity at day 
21, in response to reciL2 (1000 U/ml). 
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It should be noted that after a culture period exceeding 2 weeks the 
percentage TCR-/CD3-16+ NK cells declined. This is probably due to the 
relatively short life span of TCR- /CD3-16+ lymphocytes in vitro, and 
this would explain the extreme difficulty to clone and exp~~d 
TCR- /CD3-16+ NK cells. Although many investigators have tried to clone 
NK cells directly from PBL fractions (6,10), or from B73.1+ sorted 
cells (21,22,23) or from LGL fractions obtained after Percell isolation 
and E-rosette 29°C depletion (9,24), until now no generally applicable 
culture system has been described for the generation of stable NK cell 
clones. With a few exceptions (10,22) NK cell clones have a life span 
of maximally 4 weeks. 
Interestingly, the preferential outgrowth of TCR+;cn3+8+ lymphocytes 
over TCR+ jCD3+ 4+ lymphocytes observed in PBL bulk cultures was leuco-
agglutinin independent. Calculation of doubling times by extrapol-
ation of data obtained under limiting dilution, showed a 18 to 20-h 
doubling time for TCR+/CD3+8+ lymphocytes compared to 22-24 h for 
TCR+ /CD3+ 4+ lymphocytes. However, cloned TCR+ /CD3+ 4+ and TCR+ /CD3+ a+ 
lymphocytes had equal doubling times of 22-25 h. Since there was no 
influence of the initial PBL subset composition on the plating effi-
ciency in limiting dilution experiments, we conclude that TCR+;cn3+4+ 
lymphocytes promote the proliferation of preactivated TCR+;cn3+8+ 
lymphocytes, probably by production of lymphokines. 
In conclusion, optimal expansion of lymphocytes, or lymphocyte 
subsets, can be accomplished by changing the concentration of leucoag-
glutinin in the culture system. 
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CHAPTER 3 
CY'lUI'OXIC LYMPHOCYTES IN PERIPHERAL BlOOD AND LUNG TUMOR TISSUE OF 
PATIENTS 
Introduction 
Human solid lung tumors often contain tumor infiltrating lymphocytes 
(TIL) (1), which may represent a favorable prognostic value (2,3) be-
cause they may exert an antitumor response (3,4). TIL isolated from 
most lung tumors comprise an enhanced percentage of the cytotoxic/sup-
pressor TCRatV /CD3+a+ lymphocyte subset as compared to PBL (5-7). 
TCR-/CD3-16+ natural killer (NK) cells are virtually absent among lung 
TIL (7-9). Moreover, TIL, but not PBL, from lung tumor patients can 
show an increased expression of the activation markers CD25 (inter-
leukin 2 [IL2] receptor) and/or HLA-DR (5-7). 
Functional analysis has shown that fresh TIL and PBL exert little or 
no antitumor activity against autologous or allogeneic lung tumor cells 
(10-12). However, autologous lung tumor cells are efficiently lysed by 
CD3+ enriched T lymphocytes (11,13). Others reported lysis of auto-
logous lung tumor cells by large granular lymphocytes (LGL), isolated 
from PBL or pleural effusions (14,15). LGL reportedly represent CD3- NK 
cells (16). TIL from solid lung tumor tissue virtually display no NK 
lytic activity against K562 (7,10,17,18). 
The in vivo escape of tumor cells may be due to a reduced number of 
cytotoxic lymphocytes in the tumor (9), or to an overall suppression of 
their activity as demonstrated for the response of lung TIL to PHA, 
which is suppressed by either autologous tumor cells (19), a subset of 
TIL (20), and possibly both. 
Nevertheless, in vitro cloning and expansion of TIL and PBL from 
lung tumor patients, thereby excluding putative suppressive effects by 
particular subsets of lymphocytes, showed a poor mitogenic response 
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(8,21), especially the TCRa~/CD3+s+ lymphocyte subset of TIL (22). 
This suppressed response of cloned lymphocytes suggests that this de-
ficient proliferative capacity is intrinsic. 
The small proportion of lymphocytes, however, that proliferated were 
TCR+;co3+ and showed cytolytic activity to autologous and/or allogeneic 
tumor cells (23-25). No TCR-/CD3-16+ NK cell clones were established. 
Here we investigated the cytolytic activities and phenotypes of 
TCR-/CD3- NK cells and TCR+;co3+ T lymphocytes expanded from TIL and 
PBL obtained from healthy donors and lung tumor patients. Cytotoxicity 
against the NK-sensitive K562 (NK activity) and NK-resistant Daudi 
tumor cells (AK activity) were determined, as well as lectin dependent 
or antibody dependent cellular cytotoxic activity (LDCC and ADCC ac-
tivity, respectively). 
Because cloning and expansion of TCR-/CD3-16+ NK cells is notori-
ously difficult, these cells were studied after culture in bulk under 
conditions which favor the expansion of TCR- NK cells over other 
lymphocyte subsets (26,27). TCR+;co3+ T lymphocytes were analysed after 
cloning and expansion in limiting dilution. 
Results show that fresh and cultured PBL from 12 patients and 11 
healthy donors have identical immunophenotypes. Also the lymphocyte 
subset composition of cytotoxic lymphocytes and their levels as well as 
types of cytotoxic activities were the same. 
Fresh TIL displayed low NK or ADCC activities, whereas TCR-/CD3- NK 
cell enriched bulk cultures displayed high levels of NK, AK or ADCC 
activities. Despite a significantly reduced plating efficiency of TIL 
as determined by limiting dilution, these lymphocyte clones showed 
comparable levels of cytotoxic activities as PBL clones either from 
patients or healthy donors. 
We therefore conclude that TIL, but not PBL, derived from lung tumor 
patients are poor cytotoxic effector lymphocytes, because of the low 
proportion of TCR-/CD3- NK cells as well as the low proportion of TCR+ 
precursor CTL with proliferative capacity. 
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Materials and Methods 
Patients and healthy donors 
Twelve patients with a primary lung tumor, but no metastasis and no 
therapy before operation, were selected. Ten patients had moderately 
differentiated squamous lung cell carcinoma and 2 large cell carcinoma. 
Seven cases were classified as T2 N0 M0 according to the TNM system (28), 
1 case as T2 N1 M0 , 3 as T3 N0 M0 , and 1 as T3 N1 M0 • PBL and TIL were iso-
lated from 12 patients, 11 male and 1 female. Eleven patients ranged in 
age from 60 to 76 and 1 patient was 27. PBL from 11 male healthy donors 
were used, ranging in age from 50 to 64. 
Isolation of TIL 
Single cell suspensions were made of mechanically and enzymatically 
dispersed fresh lung tumor tissue. Sections of 1-1.5 cm3 were exten-
sively washed with sterile RPMI 1640 (Flow Laboratories, UK), buffered 
with bicarbonate (2 g/1) and Hepes (4.8 g/1) and supplemented with 10% 
heat-inactivated fetal calf serum (FCS), 100 IU/ml penicillin/strepto-
mycin and 4 mM glutamine. Blood clots were removed with a scalpel and 
the tissue was further minced with scalpels and then forced through a 
nylon filter. The flow through was centrifuged, washed twice and resus-
pended in medium. In 2 cases the tissue remaining on the filter was 
washed in RPMijHepes plus antibiotics without serum and incubated for 
10-20 min at 37°C with a mixture of collagenase (2 mgjml), trypsine 
(2 mgjml), and DNase (0.2 mg/ml) in RPMijHepes plus antibiotics. All 
chemicals were purchased from Sigma Chemical Co., St. Louis, USA. The 
suspension was again forced through a nylon filter and the flow through 
was washed twice in medium plus 10% FCS. Lymphoid and nonlymphoid cells 
were separated by centrifugation on a two-step Ficoll gradient (100% 
and 75% Ficoll-Isopaque, Pharmacia Fine Chemicals, Uppsala, Sweden) 
(29). The low density cell fraction was enriched for tumor cells and 
the high density cell fraction for lymphocytes. The viability of TIL 
exceeded 90% as determined by trypan blue exclusion. In only 6 cases 
the yield of viable TIL allowed phenotypical and/or functional analy-
sis. Contamination with tumor cells ranged from 0-30% in these TIL 
fractions. After the isolation procedure, TIL were incubated for 16 h 
in RPMI/10% FCS at 37°C before use in experiments. 
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Isolation of PBL 
PBL were isolated from healthy donors or lung tumor patients prior 
to surgery by centrifugation on Ficoll-Isopaque (d=l.077 gjcm3 ). The 
percentage of lymphocytes was determined by May-Grtinwald Giemsa stain-
ing of cytospin preparations or by immunophenotyping using an anti-CD2 
mAb. PBL were directly used or cryopreserved in liquid nitrogen. 
In vitro lymphocyte cultures 
TIL and PBL were cultured in bulk (3000/Well) in 96 well round bot-
tomed microtiter plates (Greiner Labor Technik, Phidelsheim, FRG) with 
y-irradiated (25 Gy) feeder cells: allogeneic PBL (2xl04 cells/well) 
and Epstein Barr virus (EBV) transformed lymphoblastoid B cell lines 
(104 cellsjwell) (21). RPM! 1640/Hepes culture medium, supplemented 
with 10% pooled human serum, 4 mM glutamine, 1 pgjml indomethacin and 
100 IU penicillin/streptomycin was added in a total volume of 200 pl 
per well. Two sources of IL2 were used; either 20% of the MLA144 cell 
line culture supernatant, which contained 100 U/ml IL2 as determined 
with the IL2 dependent murine cell line CTLL-2 (22), or 25 U/ml 
recombinant ( rec) human IL2 ( EuroCetus, Amsterdam, The Netherlands) . To 
obtain selective proliferation of TCR-/CD3-16+ NK cells, no lectin was 
added to the culture medium (27). 
Plates were incubated at 37°C in 5% atmosphere of C02 • Lymphocytes 
were harvested, counted and replated with new feeder cells in fresh 
medium at weekly intervals. 
Cloning and expansion of lymphocytes 
Lymphocyte clones were generated by limiting dilution as described 
previously (21). In short, PBL and TIL were plated at 0.5, 1, 3, 10, 
30, 100 and 300 lymphocytes per well with culture medium plus 1 pg/ml 
leucoagglutinin (HA15, Pharmacia, Uppsala, SWeden) and irradiated fee-
der cells (as described above). Microtiter wells were microscopically 
screened for the presence of proliferating lymphocytes. The plating 
efficiency (PE) was calculated by the minimum X2 method from a Poisson 
distribution relationship between the logarithm of the percentage of 
negative wells and cell number (31). Between day 12 and 15, prolifer-
ating lymphocytes were transferred into 8-24 wells containing fresh 
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medium and new feeder cells. 
plated weekly. 
Thereafter, cloned lymphocytes were re-
Immunophenotype 
Fresh; bulk cultured and cloned PBL and TIL were immunophenotyped 
using a panel of mAb: anti-CD2 mAb CLB Tll.l (CLB, Amsterdam, The 
Netherlands); anti-CD3, anti-CD4 and anti-CD8 mAb OKT3, OKT4 and OKT8 
(Ortho Pharmaceutical, Raritan, NJ, USA); anti-CD16 mAb VD2 (CLB FeR 
gran 1, kindly provided by Dr. T. Huizinga, CLB, Amsterdam, The Nether-
lands); anti-CD25 mAb Tac (kindly provided by Dr. T. Uchiyama, Kyoto, 
Japan) and anti-HLA Class II mAb 7.5.10.1 (kindly provided by Dr. M. 
Jonker, TNO Rijswijk, The Netherlands). The fluorescein isothiocyanate 
conjugated goat anti-mouse IgG Ab was purchased from Nordic, Tilburg, 
The Netherlands. Lymphocytes were labeled with mAb and analysed with a 
fluorescence activated cell sorter (FACS II) (Becton Dickinson, Sunny-
vale, California, USA) as described (32). 
Determination of cytotoxicity 
Cytotoxic activity was measured in triplicate in a 3-h 51 Cr release 
assay (32). A panel of histologically distinct tumor cell lines was 
used as target cells: K562, an erythromyeloid cell line; Daudi, a 
Burkitt's lymphoma derived cell line; and P815, a mouse mastocytoma 
derived cell line. Fresh tumor cells could not be used as target cells 
due to the low number of viable cells obtained. Lectin dependent cellu-
lar cytotoxic (LDCC) activity was determined by 15 min preincubation of 
51 Cr labeled P815 cells with 100 pg/ml leucoagglutinin followed by 
washing. Antibody dependent cellular cytotoxic 
determined by preincubation of 51 Cr labeled P815 
(ADCC) activity was 
cells with rabbit 
anti-P815 Ab (1/40 final dilution of ascites), followed by washing. The 
standard error of the mean percentage lysis in triplicate determi-
nations never exceeded 8% and was omitted for the clarity of presen-
tation. 
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Results 
Cytolysis by PBL and TIL 
Twelve PBL fractions and 5 TIL fractions from lung tumor patients 
and 11 PBL fractions from healthy donors were tested for cytolytic 
activity. In order to compare the magnitude and type of cytolytic ac-
tivities displayed by these lymphocyte fractions, LDCC, ADCC, NK and AK 
activity were determined. NK activity was tested against K562 cells, 
and NK-resistant Daudi cells were used to determine AK activity (for 
review, 33). PBL from both patients and healthy donors exerted similar 
ranges (5-60%) and average levels of NK, LDCC or ADCC activity, 
(Figure 3.1A). Moreover, all PBL fractions displayed low AK activity 
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Figure 3.1A Cytolytic activity of PBL from 12 lung tumor patients (II ) 
and 11 healthy donors ( 8). PBL from 1 healthy donor were 
not tested for AK activity. Effector to target cell (E/T) 
ratio was 27. 
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(range 0-20%). The 5 TIL preparations showed equal AK and LDCC activi-
ties as their autologous PBL (Figure 3.1B). In contrast, all 5 TIL 
preparations exhibited markedly lower levels of NK or ADCC activities 
than their autologous PBL or PBL derived from healthy donors. 
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Figure 3.1B cytolytic activity of fresh TIL from 5 lung tumor patients 
and their autologous PBL ( •, ..t.., e , T, +). TIL from 1 
patient (..t..) were not tested for NK and AK activity. EjT 
ratio was 27. 
IIIDIDIDOphenotype of PBL and TIL 
PBL 
One explanation for the variability in cytolytic activities between 
individuals is a difference in lymphocyte subset composition of PBL or 
TIL. Therefore, the percentages of CD3, CD4, CDS and CD16 positive 
lymphocytes were determined. To identify activated lymphocytes, HLA-DR 
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and CD25 cell surface expression was determined. The range and mean 
percentages of CD3,4,8 and 16 positive lymphocytes in PBL from patients 
and healthy donors were about equal (Table 3.1). Also about equal per-
centages of lymphocytes expressed CD25 and HIA-DR (57% and 5 12%), 
respectively (Table 3.1), indicating the presence of a low percentage 
of in vivo activated lymphocytes. 
Table 3.1 PBL from lung tumor patients and healthy donors have simi-
lar phenotypes. 
Surface antigen 
CD3 
CD4 
CDS 
CD16 
CD25 
HIA-DR 
Patients 
(n=8)al 
66 ± 7 (55-75) 
41 ± 5 (35-50) 
29 ± 9 (17-42) 
20 ± 9 (9-33) 
7 ± 3 (0-12) 
10 ± 5 (0-18) 
PBL 
Healthy donors 
(n=8)a) 
68 ± 10 (54-78) 
47 ± 10 (28-60) 
27 ± 13 (18-53) 
19 ± 8 (6-29) 
5 ± 3 (0-10) 
12 ± 3 (7-15) 
a) Data are expressed as mean percentage positive lymphocytes plus 
standard deviation. The range is given in parenthesis. 
TIL 
NK and ADCC activities are predominantly displayed by TCR-/CD3-16+ 
lymphocytes, albeit that activated TCRyo+;co3+ T cells may also exert 
NK, AK or ADCC activities (34-36). The low NK or ADCC activity of TIL 
may therefore be due to a decreased proportion of TCR-/CD3-16+ NK cells 
in TIL. From only 2 tumor specimens sufficient numbers of TIL were 
isolated to allow immunophenotypic analysis. CD16+ NK cell containing 
lymphocytes could not be detected in these TIL fractions. In the 2 
corresponding autologous PBL fractions, however, 11% and 23% CD16+ 
lymphocytes were found, respectively. The CD4+;cos+ lymphocyte ratio in 
TIL was considerably lower than that in autologous PBL (patient 1: 0.43 
in TIL versus 1.19 in PBL; patient 2: 0.94 in TIL versus 1.68 in PBL). 
HLA-DR and CD25 expressing lymphocytes were not detected. 
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Functional and phenotypic analysis of in vitro activated and expanded 
PBL and TIL 
Bulk cultured PBL 
To investigate the phenotype and type of cytolytic activity of 
lymphocytes, PBL and TIL were cultured in vitro. Since it is difficult 
to establish and maintain TCR-/CD3-16+ NK cell clones, PBL were cul-
tured in bulk in IL2 containing medium plus irradiated allogeneic 
feeder cells but without leucoagglutinin, in order to selectively 
expand TCR-;cn3-16+ NK cells (27). 
After 2 weeks culture, in all except 1 case (Table 3.2A, patient 1), 
the initial percentage of CD16+ lymphocytes (on average 20%) had 
increased (healthy donors: mean 60±11%, range, 40-75%; patients: mean 
53±24%, range, 8-92%). In contrast, the initial percentage TCR+;cn3+16-
lymphocytes (67%) had decreased to on average 40% and 29% in PBL from 
patients and healthy donors, respectively. All but one CD16+ lymphocyte 
enriched fractions displayed high levels of NK, AK, LDCC or ADCC ac-
tivities (more than 50% lysis at an E/T ratio of 27) (Table 3.2A). 
Bulk cultured TIL 
Because only 2 TIL fractions contained enough lymphocytes for immu-
nophenotypic analysis, TIL from 6 patients were cultured in IL2 con-
taining medium plus irradiated feeder cells but without leucoagglutin-
in, to determine whether the low NK or ADCC activity of TIL were due 
to a relatively low proportion of TCR-/CD3-16+ lymphocytes. 
Multiplication factors for TIL were 1.5-5-fold lower than for auto-
logous PBL at 1 week of culture (data not shown). Interestingly, at 2 
weeks of culture, the mean percentage CD16+ lymphocytes in TIL was 
about 20% less than in autologous PBL (Table 3.2B), possibly due to a 
lower initial percentage of CD16+ lymphocytes in TIL, as was found for 
2 patients. These 2 TIL fractions virtually displayed no NK, ADCC or AK 
activities when cultured without leucoagglutinin. In contrast, the 
CD16+ enriched lymphocyte fractions displayed high levels of NK, AK, 
LDCC or ADCC activities (Table 3.2B). Although the major subset of 
lymphocytes lysing K562 or Daudi target cells are TCR-;cn3-16+ NK 
lymphocytes, various TCR+ /CD3+16- T lymphocyte subsets may also lyse 
these target cells (33-35). Therefore, PBL and TIL were cloned to de-
termine the percentages and subsets of precursor CTL as well as their 
type and level of cytotoxic activity. 
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Table 3.2A Cytolysis by CD16+ enriched PBL from lung tumor patients is 
comparable to that of healthy donors. 
Phenotypea l Cytolytic activitY' l 
Patient CD3 CD16 LDCC P815 ADCC NK AK 
1 80 8 73 3 51 9 1 
2 30 62 52 10 50 56 6 
3 53 50 45 0 38 52 23 
4 3 72 46 66 70 56 75 
5 35 50 59 62 76 67 72 
6c) 32 46 73 50 51 80 79 
7 43 46 46 0 56 51 57 
8 42 92 64 10 71 65 66 
Mean ± SD 40±22 53±24 57±12 25±29 58±13 55±21 47±32 
Healthy 29±20 60±11 57± 8 24±25 58±11 61±14 48±34 
donors (n=7) 
Range 5-64 40-75 43-65 0-58 41-70 41-86 9-85 
Table 3.2B Cytolysis by CD16+ enriched TIL from lung tumor patients is 
comparable to that of CD16+ enriched PBL from healthy 
donors. 
Phenotypea l Cytolytic activityhl 
Patient CD3 CD16 LDCC P815 ADCC NK AK 
1 72 0 77 5 33 17 1 
6c) 60 27d) 59 45 44 85 79 
7 82 0d) 54 0 0 0 19 
8 31 70 55 25 70 70 58 
9 65 40 69 24 76 60 76 
10 22 55 72 59 68 57 80 
Mean ± SD 55±24 32±29 64±10 26±23 49±29 48±33 52±34 
Lymphocytes were cultured for 2 weeks in IL2 containing medium plus 
allogeneic irradiated feeder cells without leucoagglutinin. 
a) Percentage positive cells. 
b) Percentage 51 Cr release at an E/T ratio of 27. 
c) Analysed after 1 week of culture. 
d) No initial CD16+ lymphocytes were detected. 
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Inmrunophenotypic, proliferative and lytic properties of cloned PBL and 
TIL 
PBL and TIL were cloned in limiting dilution in complete medium plus 
leucoagglutinin. Plating efficiencies were calculated using the Poisson 
formula and ranged from 9-59% and from 14-53% for PBL derived from 
patients and from healthy donors, respectively. The 2 TIL fractions had 
a lower plating efficiency (PE) than the corresponding PBL (patient 1: 
P~rL = 2%, PEPBL = 9%; patient 2: P~rL = 17%, PEPBL = 45%), which 
corresponded to the lower multiplication factors for bulk cultured TIL 
as compared to the corresponding autologous PBL bulk cultures. 
About 20 clones of each donor were randomly picked for functional 
and phenotypic analysis. The majority of these clones from all healthy 
donors was TCR~~;cn3+4+ (mean 70%±12%) (Table 3.3), of which only 20% 
exerted LDCC activity; about 25% was TCR~~/CD3+8+ and virtually all 
Table 3.3 Immunophenotypic and functional analysis of cloned PBL and 
TIL from lung tumor patients and healthy donors. 
Immunophenotype 
Experiment Total % TCR~/ % TCR~/ % TCRyo+ 1 % 
number CD4+ cn8+ CD4_8_ lytica 1 
PBL 1 16 62 25 12 44 
(HD) 2 20 70 25 5 35 
3 9 78 22 0 nt 
4 18 50 39b I 11 61 
5 29 79 21 0 35 
10 23 78 22 0 39 
PBL 1 17 29 71 0 47 
(P) 2 20 85 10 5 25 
3 6 83 17 0 nt 
4 9 22 67 11 78 
5 28 18 54 28 82 
8 22 64 36 0 37 
10 26 85 8 8 24 
TIL 8 25 56 44 0 64 (P) 10 29 34 62 0 73 
HD = healthy donor; P = patient; nt = not tested. 
a I Lytic is defined as 10% or more 51 Cr release above spontaneous 
release at an E/T ratio of 10 in the LDCC assay. 
b I One clone is TCR-/CD3_4_8±. 
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displayed LDCC activity, but only occasionally NK activity. No AK ac-
tivity was observed. In 3 out of 6 healthy donors also TCRyo+;cn3+4-a-
clones were obtained and these all showed NK, AK, LDCC or ADCC activi-
ties (data not shown). 
In contrast to healthy donors, the majority of PBL clones from 3 
lung tumor patients were TCR~ /CD3+ a+ • Again, only 20% of the 
TCR~ /CD3+4+ clones showed LDCC activity and, occasionally, NK ac-
tivity. The levels of cytolytic activities of all the TCR~/CD3+a+ 
clones were comparable to that of healthy donor derived TCR~/CD3+a+ 
clones. In PBL from 1 patient a high percentage of TCRyo+;cn3+4-a-
c1ones (28%) was found (Table 3.3, experiment 5), which exerted NK, AK, 
LDCC and occasionally ADCC activities. 
In 1 of the 2 TIL fractions studied, the number of TCR~/CD3+a+ 
clones was significantly increased as compared to the number derived 
from its autologous PBL. 
Discussion 
one of the mechanisms underlying the in vivo escape of tumor cells 
from the immunosurveillance may be an insufficient number of cytolytic 
lymphocytes that can be recruited. Alternatively, precursors of cyto-
toxic lymphocytes are present, but their cytotoxic potential becomes 
blocked due to suppressor mechanisms. 
To address these questions fresh and cultured PBL as well as TIL 
from lung tumor patients were immunophenotypica1ly and functionally 
analysed using mAb and by determination of NK, AK, LDCC and ADCC ac-
tivities, respectively. Fresh PBL from lung tumor patients and healthy 
donors displayed similar phenotypic features. In contrast, fresh TIL 
contained no CD16+ lymphocytes and the CD4+;cna+ lymphocyte ratio was 
decreased as compared to their autologous PBL, in agreement with others 
(5-9). No lymphocytes were found in PBL or TIL expressing elevated 
levels of the activation markers CD25 and HLA-DR as compared to PBL 
from healthy donors, confirming the findings of Whiteside et al. (8). 
However, this contrasts with data obtained by others, who found more 
than 30% CD25+ lymphoid cells in lung tumors, respectively (6,7). Dif-
ferences in stage and histology of the lung tumors may explain these 
differences. However, also the different methods of detection, i.e. 
immunohistologic evaluations of lung tumor sections (6) versus iso-
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lation of TIL by enzymatic processing of lung tumor tissue may account 
for the different results (this manuscript, 7). The lack of detectable 
levels of CD25+ , HLA-DR+ or CD16+ lymphocytes was not due to enzymatic 
digestion of the tumor tissue, because we obtained similar results with 
TIL derived from mechanically dispersed tumors. Moreover, although 
enzyme treatment decreased lymphocyte surface expression of CD16 and 
HLA-DR, it was fully recovered after incubation for 18 h in medium 
without enzymes (unpublished observations, 25). 
In contrast to PBL, TIL exerted virtually no NK or ADCC activities. 
Firstly, NK and ADCC activities may be suppressed by tumor cells or 
subsets of TIL. Secondly, only a few TCR-/CD3-16+ NK cells may be pres-
ent in TIL (7,9, Table 3.2B), and those NK cells may be unable to lyse 
more than one target cell (18). 
To exclude putative suppressive effects by tumor cells or subsets of 
TIL, and to phenotypically analyse the various types of cytotoxic 
lymphocytes and their precursors, PBL and TIL were cultured in bulk and 
cloned in limiting dilution and expanded (25). Since it is notoriously 
difficult to clone and expand CD3-16+ NK cells for prolonged periods of 
time, CD16+ enriched lymphocyte bulk cultures were used (27). At 2 
weeks of culture PBL were enriched for CD16+ lymphocytes from initially 
20% to 53% and from 20% to 60% for patients and healthy donors, re-
spectively. However, TIL cultured in bulk for 2 weeks contained on av-
erage 32% CD16+ NK cells, indicating that the proportion of 
TCR-;co3-16+ NK cells is relatively small in TIL, as indeed shown for 2 
patients. In spite of the lower overall multiplication factor for bulk 
cultured TIL, there was no initial lag time of proliferation of CD16+ 
lymphocytes from lung cancer, as was reported for CD16+ TIL isolated 
from untreated primary squamous cell carcinomas of the head and neck 
(37). 
CD16+ enriched PBL from patients or healthy donors exerted similar, 
high levels of NK (55% and 61% lysis, respectively), AK (47% and 48% 
lysis, respectively) and ADCC activities (58% and 58% lysis, respect-
ively). Unexpectedly, in spite of the lower percentage of CD16+ TIL 
these lymphocytes exerted comparable levels of NK, AK and ADCC activi-
\ 
ties as control PBL, suggesting an enhanced recycling capacity, i.e. 
individual CD16+ TIL can lyse more target cells per unit of time. 
It should be noted that the percentage of lysis, also of K562 or 
Daudi cells, is the net effect of lytic activities of all subsets of 
lymphocytes and not only of TCR-/CD3-16+ NK cells. Indeed, TCR+;co3+ 
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T lymphocyte subsets display MHC-unrestricted lysis upon activation in 
vitro (33,34,37). Limiting dilution analysis was therefore performed to 
determine the fraction size of these TCR+/CD3+ lymphocyte subsets and 
their cytotoxic activities. 
The plating efficiency for PBL from healthy donors and patients 
ranged from 14-53% and 9-59%, respectively. TIL, however, showed a 
3-4-fold lower plating efficiency than their autologous PBL. Although 
only 2 TIL fractions could be tested, our data are in agreement with 
those of others, who also found a 2-50-fold lower plating efficiency 
for lung TIL as compared to PBL (8,21). The majority of PBL clones 
derived from healthy donors were TCR+;co3+4+, but PBL clones of 3 out 
of 7 patients were TCR+jco3+a+. These contrasting data might be due to 
different subsets of lymphocytes within the CD4+ or cos+ lymphocyte 
fractions, which differ in proliferative capacities. 
Subset differences within the CD4+ or cos+ lymphocyte fractions 
might also account for the higher proportions of TCR+;co3+s+ clones 
generated from TIL. In addition, this might be due to the higher in-
itial percentage CDS+ lymphocytes in TIL. 
Despite the reduced plating efficiency of TIL, more than 60% of the 
established clones displayed LDCC activity and, occasionally, NK ac-
tivity. On average 48% and 43% LDCC clones could be generated from 
autologous PBL and healthy donors respectively. Phenotypic analysis 
showed that virtually 100% cos+ clones and about 20% of the CD4+ clones 
from TIL and PBL exerted LDCC activity, confirming data by Miescher et 
al. (22). 
In conclusion, fresh TIL, but not PBL, from lung tumor patients, 
contain a low proportion of TCR-/CD3-16+ NK cells. Moreover, 
TCR~/CD3+ lymphocytes in TIL, but not in PBL, showed a decreased 
proliferative capacity in vitro, indicating that the proportion of in 
vivo TCR+ precursor CTL that can be recruited may be reduced. 
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CHAPTER 4 
INDUCTIOO OF LYSIS BY TCRyo+ /CD3+ T LYMPHOCYTES VIA C02 ~RES 
TRIGGERING VIA THE Tll.l EPITOPE OOLY 
Introduction 
The 50 kDa transmembrane glycoprotein C02, originally identified as 
the sheep red blood cell· (SRBC) receptor is also known as Tll or 
lymphocyte function associated antigen 2 (LFA-2). C02 is involved in 
both cell-cell interactions and lymphocyte activation (1-5). CD2 is the 
earliest differentiation antigen to appear in human T cell ontogeny and 
is expressed on virtually all thymocytes, mature TCR+/CD3+ and 
TCR-/CD3- NK cells (5-7). Three distinct epitopes, T11.1, T11.2 and 
T11.3 have been identified on the CD2 molecule (1,2). The T11.1 epitope 
is associated with the SRBC binding site whereas the T11.2 and T11.3 
epitopes are not. Activation of TCR~/CD3+ T cells through the 
"alternative" CD2 pathway requires two stimuli, i.e. a combination of 
two anti-CD2 mAb recognizing different CD2 epitopes (1,8-10) or a 
single anti-CD2 mAb plus either PMA (11) or submitogenic concentrations 
of PHA (3). The activation ofT cells through CD2 may induce IL2 recep-
tor (R) expression (1,12), IL2 production (10), IL2 dependent prolif-
eration (2), and may trigger the cytolytic mechanism (3,13,14). 
In contrast, activation of the cytolytic mechanism of TCR-/CD3- NK 
cells via CD2 can be obtained by both a mitogenic combination of two 
anti-CD2 mAb (T11.2 and T11.3) (15) and by a single anti-CD2 rnAb 
(3,16). Induction of cytotoxicity by a single anti-CD2 rnAb however 
requires crosslinking of CD2 and CD16 (16,17). Thus activation trig-
gered via CD2 may employ different pathways in TCR~/CD3+ T cells and 
NK cells (2,3). 
T cells expressing the TCRyo+/CD3+ complex on their cell surface 
share characteristics with both TCR-/CD3- NK cells and "classic" 
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TCR<XI3'" /CD3+ lymphocytes (18-20). All three lymphocyte subsets express 
CD2, can be induced to express IL2R, and subsequently show IL2 depen-
dent proliferation. TCRy&+;cn3+ cells resemble TCR-/CD3- NK cells in 
the expression of FcyRIII (CD16), in the ability to exert FcyRIII me-
diated ADCC and, upon activation, in the ability to display MHC-unre-
stricted cytotoxic activity (18-20). TCRatr/CD3+ and TCRyo+;cn3+ T 
cells both express polymorphic TCR that is noncovalently associated 
with CD3 proteins. These TCR are involved in antigen specific recog-
nition (21,22) which may be MHC-restricted (21, Danuta Kozbor, personal 
communication) • 
In the present study we examined the requirements to trigger lysis 
via the CD2 activation site in human TCRyo+;cn3+ clones. To this end we 
used bispecific Ab-heteroconjugates, containing a mAb directed against 
an activation site on the effector cell which is covalently coupled to 
an antibody directed against a target cell bound determinant. Bi-
specific mAb efficiently bridge target cells and effector cells and 
subsequently trigger the lytic machinery of the effector cell (23,24, 
25,26). 
In the experiments described herein we used an Ab-heteroconjugate 
containing anti-CD2 mAb crosslinked to anti-DNP Ab (anti-CD2 x anti-
DNP) to target TCRyo+;cn3+ clones against TNP coated target cells. It 
was demonstrated that heteroconjugates containing a single anti-CD2 mAb 
(OKT11) can induce cytotoxic activity in human TCRyo+;cn3+ T cell 
clones, but not in TCRatr /CD3+ T cell clones, and that CD2 is func-
tionally linked to the TCRyo/CD3 pathway. 
Materials and Methods 
cytotoxic clones 
The following clones were used as effector cells in the cytotoxicity 
assay: the TCR-/CD2+,3- NK cell clones NK76 and NK77, obtained by 
limiting dilution of PBL from a patient with Ty lymphocytosis (27); 
clone WIK {TCRyo+;cn2+3+), kindly provided by Dr. D.A. Hafler (Harvard 
Medical School, Boston, USA) (28); the TCRyo+;cn2+3+ clones AK1005 and 
AK4 and the TCRatr ;cn2+3+ clones Dll (Cw3 specific), G9 (Cw3), N+20 
(Drw6), 609, 546 and 643, derived from PBL of healthy donors (29). 
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Clones were cultured in 96 well round bottomed microtiter plates 
(Greiner Labor Technik, Phidelsheim, FRG) as described (29). In short, 
1-3x103 cloned cellsjWell were stimulated with 2x104 irradiated (25 Gy) 
allogeneic PBL plus 1x104 irradiated (25 Gy) EBV transformed lympho-
blastoid B cell lines (BSM and APD) in a volume of 200 pl. The culture 
medium was RPM! 1640 (Flow Laboratories, Rockville, M.D.) buffered with 
bicarbonate (2 g/1) and HEPES (4.8 g/1) and supplemented with 10% 
non-heat-inactivated (pooled) human serum, 25 U/ml recombinant IL2 
(EuroCetus, Amsterdam, The Netherlands), 4 mM glutamine, 100 IU/ml 
penicillin and streptomycin, 1 pg/ml indomethacin and 1 pg/ml leucoag-
glutinin (HA15, Pharmacia, Uppsala, Sweden). Clones were harvested and 
replated with new feeder cells and fresh medium at weekly intervals. 
Target cells 
A panel of histologically different tumor cell lines·was used as 
target: APD, an EBV transformed B cell line; Licr-Lon, a leukemic 
plasma cell line; Raji, a B cell line derived from a patient with 
Burkitt's lymphoma, Molt-4, a T cell line; K562, an erythromyeloid cell 
line; GLC-2, a lung tumor derived cell line; IgR39, a melanoma derived 
cell line and Bonnet, a fibroblast cell line. 
Antibodies 
The following purified IgG antibodies and Fab fragments thereof were 
used to prepare heteroconjugates: OKT11 (IgG1), a mAb against the CD2 
T11.1 epitope, obtained from Ortho Pharmaceutical Corp. (Raritan, 
NJ) ; OKT3 ( IgG2a) , a mAb against CD3 ( 30) ; w6/32 ( IgG2a) , a mAb 
against a common epitope on HLA Class I molecules (31) and purified 
rabbit anti-DNP antibodies (32). The Fab fragments of mAb, OKTll, w6/32 
and anti-DNP were prepared by papain digestion and did not contain any 
intact antibody as judged by SDS page (32). Bispecific heteroconjugates 
were prepared with the use of the crosslinking reagent N-succinimidyl-
3-(2-pyridyldithiol propionate) (SPDP) as described in detail (32). 
Heteroconjugates used in this study were: anti-CD2 x anti-DNP; anti-CD2 
(Fab) X anti-DNP (Fab); anti-CD3 X anti-DNP; anti-HLA Class I x 
anti-DNP and anti-HLA Class I (Fab) x anti-DNP (Fab). mAb used for 
inhibition of cytotoxicity were OKTll (anti-CD2) and CLB FeR gran 1 
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(VD2), a mAb against CD16, which was kindly provided by Dr. T. Huizinga 
(Central Laboratory of the Red Cross Blood Transfusion Service, Amster-
dam, The Netherlands). 
Assay for cytotoxic activity 
Cytotoxic activity was measured in a standard 3-h 51 Cr release assay 
(20). Briefly, varying numbers of effector cells were seeded in tripli-
cate in 75 pljWell in 96 well round bottomed microtiter plates. The 
Ab-heteroconjugate (75 pl) was added to the microtiter well at various 
concentrations, 30 min before addition of 100 pl 51 Cr-labeled target 
cells. Target cells were TNP modified by incubation with 0.3 mM 
trinitrobenzene sulfonate for 15 min at 37°C followed by washing. 
Ab-heteroconjugate induced cytotoxicity was blocked with mAb by the 
simultaneous addition of 50 pl mAb and 50 pl heteroconjugate to 50 pl 
effector cells 30 min prior to the addition of 100 pl target cells. 
Data are expressed as the mean percentage specific lysis in triplicate 
determinations. The standard error of the mean percentage lysis never 
exceeded 5% and was omitted for reasons of clarity of presentation. 
Results 
A single anti-cD2 mAb containing heteroconjugate shows differential 
activation of TCRyo+; 'l'CRctS+ and TCR- cloned lymphocytes 
To analyse the ability of the CD2 and CD3 antigens to act as acti-
vation sites for the induction of cytotoxic activity in distinct 
subsets of cloned lymphocytes, anti-CD2 x anti-DNP and anti-CD3 x anti-
DNP heteroconjugates were tested for their capacity to induce lysis of 
various TNP modified tumor cell lines. Anti-CD2 x anti-DNP heteroconju-
gate comprising the anti-Tll.l mAb, induced lysis of all TNP modified 
tumor cells by both Tar /CD3- NK cell clones and by TCRyo+ /CD3+ T cell 
clones but not by TCR~/CD3+ T cell clones (Table 4.1). All clones 
expressed about equal levels of CD2 (Figure 4.1). The inability of 
anti-co2 x anti-DNP heteroconjugate to retarget TCR~/CD3+ T cell 
clones appears to be characteristic for all TCR~/CD3+ lymphocytes, 
irrespective whether these cells express CD4 or CDS and recognize HLA 
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Class II or HLA Class I determinants, respectively (Table 4.2). Even a 
fifty times higher concentration of anti-CD2 x anti-DNP heteroconjugate 
(5 pg/ml) did not trigger the lytic machinery in TCR~ /CD3+ cloned 
cells (data not shown): only lysis of the NK sensitive target K562 
(Table 4.1) was moderately enhanced by anti-CD2 x anti-DNP heteroconju-
gate, but this was also observed using anti-HLA Class I x anti-DNP 
heteroconjugates probably resulting from increased conjugate formation 
of susceptible K562 targets to already lytic effector cells. 
Table 4.1 Targeting of lysis mediated by cloned T and NK cells, by 
anti-CD2 and anti-CD3 containing Ab-heteroconjugates. 
% lysis of TNP-target cells 
Target cell 
Effector Addition K562a) clone Molt APD Raji Licr-Lon GLC-2 IgR39 Bonnet 
TCR<>l3+/CD2+3+ medium 23b) 57c) 1 (D11) 
:~~~=~~; xd) 66 53 57 58 78 33 22 48 
anti-CD2 X 
anti-DNP 42 49 1 
TCRyli+/CD2+3+ medium 11 19 1 15 13 (AK4) 
anti-CD3 X 
anti-DNP 60 52 10 66 47 44 16 36 
anti-CD2 X 
anti-DNP 61 60 49 80 56 60 65 51 
TCR-/CD2+3- medium 69 51 73 38 1 13 (NK76) 
anti-CD2 X 
anti-DNP 71 71 54 85 76 72 58 65 
a) For histological origin of target cells see Materials and Methods. 
bl % specific lysis in a 3-h 51 Cr release assay is given at an E/T 
ratio of 9. 
c) Target Licr-Lon expresses the HLA Class I antigen (CW3) specifically 
recognized by clone Dll. 
dl Heteroconjugates (0.1 pg;ml, final concentration) were added to the 
effector cells 30 min before TNP-target cells. 
65 
Table 4.2 Anti-CD2 x anti-DNP Ab-heteroconjugate does not induce 
lysis by TCRcxtV /CD3+ T cell clones. 
% lysis of TNP-tumor cells 
Effector Addition Licr-Lon BSM APD 
clone 
TCR!fll+/CD3+ (609) 
anti-CD3 ~ anti-DNPc} 1a) 1 70b) CDS 59 77 67 
anti-CD2 X anti-DNP 2 73 
TC:1;1l+/CD3+ (G9) 24b) 47b) 2 
CDS anti-CD3 X anti-DNP 56 so 7S 
anti-CD2 X anti-DNP 30 60 5 
TCR!fll+/CD3+ (546) 7 13 1 
CDS anti-CD3 x anti-DNP 77 70 71 
anti-CD2 X anti-DNP 15 3 
TCR ll+ /CD3+ (N+20) 1 2 52b) 
CD4!f anti-CD3 x anti-DNP 27 26 52 
anti-CD2 X anti-DNP 2 0 59 
TCRooll+/CD3+ (643) 2 3 0 
CD4+ anti-CD3 X anti-DNP 47 37 45 
anti-CD2 X anti-DNP 2 5 
a) Percent specific lysis in a 3-h 51 Cr release assay is given at an 
E/T ratio of 9. 
b) Target cells expressed the HLA antigens specifically recognized by 
that clone. Clone G9 is CW3 specific; clone N+20 recognizes Drw6. 
The antigenic specificity of clones 609, 546 and 643 are unknown. 
c' Het.eroconjugates ( 0.1 pg/ml, final concentration) were added to the 
effector cells 30 min before TNP coated target cells. 
The anti-CD3 x anti-DNP heteroconjugate triggered the lytic machin-
ery of both, TCRcxtV /CD3+ and TCRyo+ ;co3+ clones. As expected, TCR- /CD3-
NK cell clones could not be induced to lyse TNP modified target cells 
with anti-CD3 x anti-DNP heteroconjugate. Unmodified target cells were 
not lysed by cloned effector cells coated with heteroconjugates (data 
not shown). The level of lysis induced by heteroconjugate depended on 
the amount of heteroconjugate added (Figure 4.2). Concentrations as low 
as 4 ng/ml anti-CD2 x anti-DNP heteroconjugate were effective in trig-
gering the lytic machinery, and half maximal lysis was achieved at 
about 15 ngjml. 
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CoNTROL 
CoNTROL 
CoNTROL 
OKT 11 
TCRcrtnCD3+ 
(CAK11) 
OKT 11 
TCR-y/i"';Co3+ 
(AK1005) 
OKT 11 
Figure 4.1 Cell surface expression of CD2 
on cloned TCRcxi3'" /CD3+ ( CAK11 ) , 
TCRyo+ /CD3+ (AK1005), and TCR-1 
CD3- (NK77) cells. 
Clones were stained with 
anti-T11.1 mAb (OKTll, 1/100 
dilution of ascites). FITC-con-
juga ted goat anti-mouse Ig 
serum (dilution 1/40) (Nordic, 
Tilburg, The Netherlands) was 
used as second reagent. Cells 
were analysed with a FACScan 
(Becton Dickinson, Sunnyvale, 
California). 
log fluorescence intensity , 
Figure 4.2 Induction of cytotoxic ac-
tivity by anti-CD2 x anti-
DNP Ab-heteroconjugate is 
dose dependent. 
% lyals 
50 
TCRyo+co3+ clone AK1005 
was tested at E/T 30 for 40 
induction of lysis on TNP-
coated melanoma cell line 
IgR39. Anti-CD2 x anti-DNP 
Ab-heteroconjugate was 
added to the effector 
cells 30 min before TNP-
IgR39 target cells. The 
y-axis represents the per-
centage lysis above back-
ground lysis. 
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FcyRIII on TCRy&+ /CD3+ clones does not participate in lysis mediated by 
anti-co2 x anti-DNP heteroconjugate 
It has been reported that the activation of the lytic machinery of 
TCR-/CD3- NK cells by a single anti-CD2 mAb required the participation 
of CD16 (FcyRIII), (17). Since some TCRy&+;co3+ clones express low 
levels of CD16 and mediate ADCC (19,20) it was possible that anti-CD2 x 
anti-DNP heteroconjugate induced cytotoxic activity by binding to 
FcyRIII on the TCRy&+;co3+ clones. Therefore heteroconjugates were 
prepared from Fab fragments. In TCRy&+;co3+ clones the anti-CD2 x 
anti-DNP and anti-CD2 (Fab) x anti-DNP (Fab) heteroconjugates induced 
comparable levels of lysis (Table 4.3). By contrast, anti-CD2 (Fab) x 
Table 4.3 Anti-CD2 (T11.1) mAb induced lysis of TNP-targets by 
TCRyo+; co3+ clones. 
Phenotype Effector 
clone 
TCRyS+/CD3+ (AK1005) 
TCRyS+/CD3+ (AK4) 
TCRyS+/CD3+ (WIK) 
TCR-/CD3 - (NK76) 
% lysis of TNP-IgR39 cells in the 
presence of 
Medium anti-CD2 X anti-CD2 (Fab) X 
anti-DNPa) anti-DNP (Fab) 
15b) 55 55 
13 44 41 
17 30 33 
20 67 31 
a) Heteroconjugates were added to the effector cells at a final concen-
tration of 0.1 pg/ml 30 min before addition of TNP treated target 
cells. 
b) % lysis at an E/T ratio of 24. 
anti-DNP (Fab) heteroconjugate induced a small amount of lysis of TNP 
treated target cells by a TCR-/co3-16+ NK cell clone whereas the 
heteroconjugate prepared from intact antibody induced strong lysis. 
These results demonstrate that activation of TCRy&+;co3+ clones by 
anti-CD2 x anti-DNP heteroconjugate does not require interaction of the 
Fe portions of the heteroconjugate with FcyRIII on the effector cell. 
Further support for this notion comes from experiments in which we 
inhibited anti-CD2 x anti-DNP heteroconjugate induced cytolysis by 
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anti-CD2 or anti-CD16 :mAb (Table 4.4). The anti-CD2 x anti-DNP hetero-
conjugate induced cytotoxic activity of TCR-/CD3- NK cell clones was 
partly inhibited by both anti-CD2 and anti-CD16 :ml\b. In contrast, the 
heteroconjugate induced lytic activity of TCRyo+;co3+ T cell clones was 
only inhibited by anti-CD2 :mAb but not by anti-CD16 :ml\b. Again, this 
shows that FcyRIII (CD16) is not involved in the anti-CD2 x anti-DNP 
heteroconjugate triggered cytotoxicity by the TCRyo+;co3+ T cell 
clones, but does participate in lysis mediated by the NK clone. 
Table 4.4 Inhibition of anti-CD2 x anti-DNP heteroconjugate induced 
cytotoxicity in TCRyo+;co3+ clones. by anti-CD2 but not by 
anti-CD16 :ml\b. 
Addition of % lysis of TNP-IgR39 by cloned effector cells 
Heteroconjugate TCRyo+/CD3+ TCRyo+/CD3+ TCRyo+/CD3+ 
(AK1005a)) (WIK) (AK4) 
gbl 27 12 24 15 30 12 24 
none none 7 16 7 16 17 33 10 23 
none anti-CD2c} 7 5 12 16 22 12 
none anti-CD16 16 10 19 27 30 5 20 
anti-CD2 x anti-DNPd} none 23 44 24 42 47 62 48 61 
anti-CD2 X anti-DNP anti-CD2 14 21 25 38 36 52 
anti-CD2 X anti-DNP anti-CD16 20 40 18 37 54 67 28 44 
a) Cloned effector cells, clones AK1005, AK4 and NK77 are CD16+, clone 
WIK is CD16- • 
b l E/T ratio. 
cl Anti-CD2 :mAb (OKT11, 1:500 of ascites) and anti-CD16 :mAb (VD2, 
1:1000 of ascites) were added 30 min before addition of the target 
cells. 
dl Heteroconjugates were added to the effector cells at a final concen-
tration of 0.1 pg/ml. 
Only heteroconjugates directed against activation sites on the effector 
cell induce cytolysis 
To establish whether the induction of lysis requires a :mAb within 
the heteroconjugate directed against an activation site on the effector 
cell, we tested the cytotoxicity inducing capacities of heteroconju-
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gates consisting of Fab fragments of either anti-CD2 or anti-HLA Class 
I crosslinked to anti-DNP (Fab). (Table 4.5). Anti-Class I (Fab) x 
anti-DNP (Fab) heteroconjugate did not induce cytotoxic activity in 
either TCRyo+ /CD3+ or TCR- /CD3- clones. The lack of induction of cyto-
toxicity in both types of clones by anti-Class I (Fab) x anti-DNP (Fab) 
demonstrates that not all cell surface molecules on the effector cell 
are able to transduce activation signals. In contrast to TCRyo+;co3+ 
clones, in TCR-/CD3- NK cell clones high levels of cytotoxicity could 
be induced by anti-Class I x anti-DNP but not by the heteroconjugated 
Fab fragments. This suggests that the anti-Class I x anti-DNP induced 
cytotoxicity in the TCR-/CD3- NK cell clone is caused by interactions 
of Fe parts of the heteroconjugate with FcyRIII (CD16) on the surface 
of the TCR-;co3- NK cells. This activity was not detected in 
TCRyo+;co3+ clones, although low levels of CD16 were expressed by 
TCRyo+;co3+ clones AK4 and AK1005. 
Table 4.5 Specificity of anti-CD2 x anti-DNP heteroconjugate induced 
cytolysis. 
% lysis of TNP-IgR39 by cloned effector cells 
none 
Addition of 
heteroconjugate 
anti-CD2 X anti-DNPb) 
anti-Class I x anti-DNP 
anti-Class I (Fab) x 
anti-DNP (Fab) 
TCRyo+/CD3+ 
(AK1005) 
26a) 
67 
25 
23 
TCRyo + /CD3 + 
(WIK) 
23 
50 
25 
24 
a) %specific lysis at an E/T ratio of 15. 
TCRyo+/CD3+ TCR-/CD3 
(AK4) (NK77) 
12 19 
52 74 
13 61 
12 21 
bl Heteroconjugates were added to the effector cells at a final concen-
tration of 0.1 pg/ml 30 min before addition of target cells. 
CD2 and CD3 activation pathways in TCRyo+ /CD3+ cells are functionally 
linked 
In TCR~/CD3+ cells the activation through C02 by a combination of 
two anti-CD2 mAb is interconnected with the CD3 activation pathway 
(3,14,33,34). Therefore we examined whether in TCRyo+;co3+ clones, the 
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C02 and CD3 activation pathways are also functionally linked. For that 
purpose, we tested the effect of anti-CD3 rnAb on the cytotoxicity in-
duced by anti-CD2 x anti-DNP heteroconjugate. Addition of anti-CD3 rnAb 
blocked the anti-CD2 x anti-DNP heteroconjugate induced cytotoxicity of 
TCRyo+;cn3+ clones (Table 4.6). Of note, the baseline cytotoxic ac-
tivity was also inhibited. This suggests that in TCRyo+;co3+ T cells 
the CD3 and CD2 activation pathways are functionally linked. Moreover, 
CD3 also appears to be involved, either directly or indirectly, in the 
regulation of the MHC-unrestricted cytotoxic activity of TCRyo+;cn3+ T 
cell clones. 
Table 4.6 Functional linkage between C02 and CD3 activation pathways 
in TCRyo+;co3+ clones. 
% lysis of TNP-IgR39 
Addition of antibodies TCRyo+ /CD3+ TCRyo+ /CD3+ 
(AK4) (WIK) 
none 32a) 18 
anti-CD2 (Fab) x anti-DNP (Fab)b) 67 56 
anti-CD2 (Fab) X anti-DNP (Fab) + anti-CD3c) 15 14 
anti-CD3 9 3 
a) %lysis at E/T ratio of 15. 
b) Heteroconjugate (0.1 pgjml) was added to effectors 30 min before 
target cells. 
c) Anti-CD3 mAb (CLB T3/4. E, 1/5000 final concentration) was added 
simultaneously with the heteroconjugate. 
Discussion 
In the present study, the requirements for activation through CD2 in 
TCRyo+ /CD3+ clones was examined. The results demonstrate that in 
TCRyo+;cn3+ cells the requirements for activation via C02 qualitatively 
differ from those in TCR~/CD3+ cells and TCR-/CD3- NK cells. Contrary 
to the C02 activation requirements in TCR~/CD3+ cells, cytotoxic 
activity in TCRyo+;co3+ clones can be induced by heteroconjugates con-
taining a single anti-CD2 mAb, namely anti-T11.1. Activation of 
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TCRys+;co3+ clones via C02 is independent of the FcyRIII (CD16) because 
the anti-CD2 (Fab) x anti-DNP (Fab) heteroconjugate was as active as 
the heteroconjugate prepared from intact antibodies. Moreover, 
anti-FcyRIII did not inhibit anti-CD2 x anti-DNP heteroconjugate in-
duced cytotoxicity in TCRys+;co3+ clones. In TCR-/CD3- NK cell clones, 
however, the induction of cytotoxicity by anti-CD2 x anti-DNP hetero-
conjugate depended on FcyRIII (CD16) because the anti-CD2 (Fab) x 
anti-DNP (Fab) heteroconjugate induced considerably lower levels of 
lysis than the heteroconjugate prepared from intact antibodies. In 
addition, lysis induced by intact heteroconjugate was partially blocked 
by mAb against CD16 or CD2. Anti-CD2 mAb only competes with the binding 
of Fab parts of the heteroconjugate with C02 on the effector cell sur-
face but not with the interaction of IgG-Fc parts of the heteroconju-
gate with CD16. Therefore, anti-CD2 mAb only partially inhibits the 
heteroconjugate induced lysis by TCR-/CD3- NK cells. Anti-HLA Class I x 
anti-DNP heteroconjugate was unable to promote lysis by the TCRys+;co3+ 
clones (Table 4.5), indicating that not any cell surface structure on 
the TCRys+;co3+ clones will serve as signal transducer for the induc-
tion of cytotoxicity. 
How can the different activation requirements via C02 in 
TCRc#)'" /CD3+, TCRys+ /CD3+ and TCR-/CD3- lymphocytes be explained? The 
densities of the C02 on the cell surfaces of the various distinct 
clones were similar as determined by flow cytometry (Figure 4.1) and 
hence provide no explanation. The differences in activation require-
ments may however be related with the interrelation of C02 with other 
cell surface structures functionally or physically. We and others have 
shown that in TCRc#)'"jCD3+ cells, the C02 and CD3 activation pathways 
are functionally linked (3,14,33,34), 
and CD16 activation pathways are 
and that in NK clones, the C02 
interconnected (16). In the 
TCRys+;co3+ clones the C02 activation pathway is functionally linked to 
the CD3 pathway (Table 4.6), but not to the CD16 pathway (Table 4.4). 
The lack of detectable interplay between C02 and CD16 may be due to the 
low level of CD16 expression on TCRys+;co3+ clones as compared to 
TCR-/CD3- NK cell clones (20). It remains to be established whether 
such functional linkage can occur when CD16 expression on TCRys+;co3+ 
clones is enhanced, e.g. by cytokines (under investigation). Anti-CD3 
mAb inhibited C02 mediated activation of cytotoxicity. Such inhibition 
may result from blocking of a common intracellular pathway utilized in 
both C02 and CD3 mediated activation. Alternatively, anti-CD3 mAb may 
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deliver a "negative" signal which interferes non-specifically with 
multiple forms of transmembrane signaling which do not normally use 
components of the CD3 activation pathway. 
In conclusion, these results indicate that induction of cytotoxic 
activity via the C02 antigen has different activation requirements, 
involving different epitopes and possibly different mechanisms in 
TCRcxtr" /CD3+ , TCRyo+ /CD3+ T cells and TCR-/CDT NK cells. The study of 
these various activation molecules and pathways with bifunctional 
heteroconjugates is not merely of academic interest. TUmor cells are 
heterogeneous and may therefore show differential susceptibilities to 
TCRcxtr" /CD3+, TCRyo+ ;co3+ or TCR- /CD3- lymphocytes, respectively. The 
availability of various bifunctional Ab preparations with distinct 
specificities may allow the selective activation, homing and lymphokine 
production of only (a) selected subset(s) of activated lymphocytes. 
Anti-CD3 containing heteroconjugate only activates TCRyo+;co3+ and 
TCRcxtr" /CD3+ lymphocytes but not TCR-/CD3- NK cells (25,35). Anti-CD16 
containing heteroconjugate predominantly activates TCR-/CD3- NK cells 
(24,32). Here it is shown that anti-T11.1 containing heteroconjugate 
triggers lysis by TCRyo+;co3+ and to a lesser extent by NK cells, 
whereas TCRcxtr"/CD3+ cells remain unactivated. Finally, both subsets of 
T cells and NK cells can be activated by a combination of heteroconju-
gates containing both anti-T11.2 and anti-T11.3 specificities (35,36). 
The selective activation of subsets of cytotoxic lymphocytes may 
induce different repertoires of lymphokines and cytolytic activities, 
and thereby may affect the host's local immune response at the tumor 
site. Therefore these basic studies could help direct the design of 
future generations of immunotherapy of cancer. 
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CHAPTER 5 
LFA-1/ICAM-1 INTERACI'ION COACTIVATES THE CD3/'l' CELL RECEPTOR COMPLEX IN 
TRIGGERING CELL MEDIATED LYSIS 
Introduction 
T cells can be activated when the antigen specific TCR interacts 
with non-self MHC proteins or with foreign antigen bound to self MHC 
proteins (1,2). T lymphocytes may also be activated via nonpolymorphic 
cell surface receptors such as C02, CD3 or CD16 interacting with their 
ligands or mAb (3-6). Recent evidence suggests that these activation 
sites are functionally interrelated, for instance, activation via CD2 
can be regulated via CD3 and vice versa (5,6). 
The interaction between CTL and the relevant target cells results in 
target cell lysis by a multistep process (2,7). The initial adhesion 
step is the rapid formation of an intercellular bond (conjugate forma-
tion) which is antigen independent. Two major pathways of adhesion have 
been identified. First, LFA-1 on CTL interacts with intercellular ad-
hesion molecule-1 (ICAM-1) on the target cell (8,9). Second, the effec-
tor cell CD2 interacts with LFA-3 on the target cell (10-13). Sub-
sequently, antigen recognition via the TCR results in triggering of the 
CTL lytic machinery and target cell lysis (2). 
LFA-1 is a transmembrane heterodimer composed of a 180 kDa a chain 
(COlla) and a 95 kDa S chain (CD18) which is expressed by most leuco-
cytes (14-16). In addition to its adhesion function, LFA-1 has also 
been suggested to be involved in T cell activation, possibly as a sig-
nal transduction molecule, as reported for CD2 (13). Binding of anti-
LFA-la or anti-LFA-lS mAb to T cells has been shown to up- or down-
regulate, respectively, anti-CD3 mAb triggered T cell proliferation in 
the absence of intercellular adhesion (17). In mice, anti-LFA-la mAb 
enhances proliferative responses of preactivated T and B lymphocytes 
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(18,19). Finally, a unique anti-LFA-la mAb has been found to induce 
homotypic cell-cell interactions (20). 
ICAM-1 is a monomeric 90-114 kDa glycoprotein which can be expressed 
on cells of many lineages, especially at specific differentiation 
stages or after exposure of cells to certain inflammatory mediators in 
vitro or in vivo (21). Biochemical and functional studies have conclus-
ively demonstrated that ICAM-1 is one of the ligands for LFA-1 
(9,22-25). Target cell ICAM-1 is involved in adhesion to and lysis of 
target cells; however, demonstration of this role is restricted to 
target cells which express ICAM-1 as the major LFA-1 ligand (24). Fur-
thermore, ICAM-1 is a major contributor to a variety of other T cell 
responses dependent on cell-cell interaction (26-29). A previously 
suggested second ligand for LFA-1, i.e. ICAM-2, has recently been 
identified (30). However, at this point it is unclear whether binding 
of the LFA-1 to the ICAM-1 ligand molecule, not only facilitates the 
adhesion of the effector cell to the target cell, but also mediates 
signals that regulate CTL activation. 
Recent reports have demonstrated that lysis resistant Burkitt's 
lymphoma cells express low levels of LFA-1, LFA-3 and ICAM-1 (31,32). 
It was shown that Epstein Barr virus (EBV) positive biopsy cells with a 
low expression of these molecules were relatively resistant to lysis by 
specific CTL. Prolonged in vitro culture of these cells induced an 
increased expression of the molecules which was associated with a more 
efficient interaction with specific CTL. These findings prompted specu-
lation that the lack of expression of ICAM-1 and other adhesion mol-
ecules on tumor cells contributes to their escape of immunosurveillance 
(31,33,34). 
The importance of the LFA-1/ICAM-1 interaction led us to further 
study its involvement in CTLjtarget cell conjugate formation and trig-
gering of lysis. To this end, ICAM-1 positive or negative tumor cell 
lines were used as target cells and bispecific Ab-heteroconjugates, 
containing an anti-CD3 mAb which is covalently coupled to an anti-DNP 
Ab. Such bispecific reagents efficiently bridge effector cells and TNP 
modified target cells and simultaneously trigger the lytic machinery of 
the effector cell (6,35). The data demonstrate that induction of ICAM-1 
expression on target cells enhances their susceptibility to CD3 trigge-
red lysis. Associated findings suggest that this costimulatory effect 
results from enhanced conjugate formation as well as enhanced signal 
transduction by LFA-1/ICAM-1 interactions. 
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Materials and Methods 
Cytotoxic clones 
CTL clones were obtained by limiting dilution cloning under poly-
clonal activation conditions as we described earlier (5). In short, CTL 
clones were expanded in 96 well round bottomed microtiter plates 
(Greiner Labor Technik, Phidelsheim, FRG). One to 3x10 3 cloned CTL per 
well were stimulated with a mixture of irradiated (25 Gy) allogeneic 
PBL (2x104 ) and 1x104 Epstein Barr virus (EBV) transformed ly.rnphoblas-
toid B cell lines (BSM and APD) in a final volume of 200 pl. The cul-
ture medium was RPMI 1640 (Flow Laboratories, Rockville, MD) buffered 
with bicarbonate ( 2 g/1) and HEPES ( 4. 8 g/1) and supplemented with 10% 
non-heat-inactivated (pooled) human serum, 25 U/ml rec IL2 (Eurocetus, 
Amsterdam, The Netherlands), 4 mM glutamine, 100 IU/ml penicillin and 
streptomycin, 1 pg/ml indomethacin and 1 pg/ml leucoagglutinin (HA15, 
Pharmacia, Uppsala, Sweden). Clones were harvested and replated with 
new feeder cells and fresh medium at weekly intervals. 
Antibodies 
Bispecific hetero-cross1inked Ab were prepared with the use of the 
crosslinking reagent N-succinimidyl-3-(2-pyridyldithiol propionate) 
(SPDP) as described in detail elsewhere (35). Hetero-crosslinked Ab 
used in this study were: anti-CD3 (OKT3) x anti-DNP; anti-CD18 (MHM23) 
X anti-DNP and anti-HLA Class I (w6/32) x anti-DNP mAb. Anti-DNP Ab 
were purified polyclonal rabbit Ab. mAb used for the inhibition of 
lymphocyte functions and for immunofluorescence staining were: CLB54, 
(anti-CD18) (36), specific for the LFA-1~ chain, a generous gift from 
Dr. R.A.W. van Lier (CLB, Amsterdam, The Netherlands); mAb 84H10, 
(anti-ICAM-1) (9) and w6/32 (anti-HLA Class I common epitope) (37). 
Cytotoxicity assay 
Cytotoxic activity was measured in a standard 3-h 51 Cr release assay 
(5,6). Briefly, varying numbers of effector cells were added in tripli-
cate in 75 pljwell in 96 well round bottomed microtiter plates. The 
hetero-crosslinked Ab ( 75 pl) was added to the microti ter well at the 
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indicated concentrations 30 min before addition of 51 Cr-labeled target 
cells (100 pl). Target cells were incubated with 0.3 mM trinitrobenzene 
sulfonate (TNP) for 15 min at 37°C followed by washing. ICAM-1 ex-
pression on IgR39 tumor cells was enhanced by incubation with 1000 U/ml 
recombinant human TNF (recTNF) (Cetus Corp., Emmeryville, California, 
USA) for 24 h. Tumor cell lines used as target cells in this study 
include IgR39 and IgR37, melanoma derived cell lines; Licr-Lon, a 
leukemic plasma cell line; Molt-4, a T cell line, APD, an EBV trans-
formed B cell line; K562, an erythromyeloid cell line and U937, a mono-
cytic cell line (5). 
Hetero-crosslinked Ab-induced cytotoxicity was blocked with mAb by 
the simultaneous addition of 50 pl blocking mAb and 50 pl heteroconju-
gated Ab to 50 pl effector cells 30 min prior to the addition of 100 pl 
target cells, unless indicated otherwise. The standard error of the 
mean percentage lysis never exceeded 5% and was omitted for clarity of 
presentation. 
Conjugate formation assay 
Antigen independent and hetero-crosslinked Ab-induced conjugate 
formation of CTL and target cells was assessed by FACS analysis (Becton 
Dickinson, Mountain View, CA, USA) (9,38,39). CTL (5x106 ) were labeled 
with 100 pg/ml hydroethidine in a volume of 2 ml at 37°C for 25 min. 
Target cells (5x106 ) were first modified with TNP (see above) and then 
labeled with 0.05 pg/ml carboxy fluorescein diacetate (CFDA) in a vol-
ume of 2 ml at 37°C for 25 min. CTL and target cells were washed be-
fore use. Twenty microliters of labeled effector cells (107 /ml) were 
mixed with an equal amount of labeled target cells (107 jml) with and 
without Ab-heteroconjugates and/or blocking roAb. Ab-heteroconjugates 
and mAb were preincubated with the CTL for 15 min at 37°C before the 
addition of tumor target cells. The final volume was adjusted to 
100 pl. Conjugate assay medium was RPMI 1640 supplemented with 10% FCS. 
CTL and target cell mixtures were centrifuged for 5 sec in a serofuge 
and conjugates were allowed to form at 21°C for 10 min. Conjugate for-
mation was stopped by the addition of 1 ml ice-cold PBS + 1% BSA. Cells 
were innnediately resuspended and analysed on a FACScan. Ten thousand 
total fluorescent events were collected and the number of events emit-
ting simultaneously red and green fluorescence (conjugates) was divided 
by the total number of events emitting red fluorescence (total effector 
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cells) yielding the percentage of CTL that had formed conjugates. No 
conjugates were observed when CTL and target cells were mixed and 
analysed immediately. 
Immunofluorescence assay 
Five x 105 cells were pelleted and incubated with 10-20 pl mAb at 
4°C for 30 min. After washing, the cells were incubated with 10 pl 1:40 
diluted goat anti-mouse Ab, conjugated with FITC (Nordic, Tilburg, The 
Netherlands). The cells were washed twice with PBS+ 1% BSA + 0.01% 
Sodium Azide and analysed on the FACScan. 
Results 
Melanoma IgR39 is relatively resistant to CD3 mediated lysis 
A panel of histologically distinct tumor cell lines were compared 
for their susceptibility to lysis by TCR~/CD3+ and TCRy8+;co3+ CTL 
clones triggered via CD3, using hetero-crosslinked anti-CD3 x anti-DNP. 
Most tumor cell lines were susceptible to CD3 mediated lysis (Fig-
ure 5.1). The melanoma derived cell line IgR39 however showed a rela-
tive resistance to CD3 mediated lysis. This was found for both TCR~ 
and TCRy8+ CTL and hence is independent of the sublineage of the CTL. 
The level of CD3 mediated lysis depended on the amount of anti-CD3 
added. At higher anti-CD3 concentrations (15 ngjml or more) the tumor 
cell line IgR39 was effectively lysed (Figure 5.1). Thus, the relative 
resistance to CD3 mediated lysis by cloned TCR~ and TCRy8+ CTL can be 
overcome at higher effective densities of anti-CD3 mAb on the target 
cells. 
Expression of cellular adhesion molecules on tumor cells 
Because the relative resistance of IgR39 target cells to CD3 me-
diated lysis was independent of the CTL clone used, it was hypothesized 
that the composition of surface molecules on the target cells, particu-
larly the known ligands for CTL/target cell interaction ICAM-1 and 
LFA-3, determined its relative resistance to CD3 mediated lysis by CTL. 
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The TNP modification of the IgR39 cells was not the cause of the rela-
tive resistance because IgR39 target cells reportedly showed comparable 
levels of sensitivity to C02 mediated lysis as other tumor cell lines 
(6). The expression of LFA-3 and ICAM-1 on the tumor cell lines was 
determined. Contrary to the panel of other cultured tumor cells tested 
in Figure 5.1, the IgR39 cells lacked surface expression of ICAM-1 
(Figure 5.2). All human tumor cell lines tested here expressed LFA-3. 
TNP modification of the tumor cell lines did not affect expression of 
ICAM-1 and LFA-3 (data not shown). 
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Figure 5.1 IgR39 melanoma cell line is relatively resistant to CD3 
mediated lysis by TCRyS+ /CD3+ clone WiK (panel A) or 
TCR<#V /CD3+ clone Dll (panel B) • 
TNP modified tumor cell lines used as target cells were: 
D, IgR39; +, IgR37; x, APD; 1:.., Molt-4; 0, Licr-Lon; \1, 
K562 and 0, U937. Target cell lysis was induced by ad-
dition of the indicated concentration hetero-crosslinked 
anti-CD3 mAb. Target cell line Licr-Lon expressed the HLA 
Class I antigen Cw3, specifically recognized by TCR<#V/CD3+ 
clone D11. EfT ratio was 10. 
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Figure 5.2 TNF induces ICAM-1 expression on the ICAM-1- melanoma cell 
line IgR39. 
IgR39 was cultured in the presence of 1000 U/ml recTNF 
for 24 h. 
The "resistance" of IgR39 target cells to CD3 mediated lysis is due to 
lack of ICAM-1 expression 
To assess the functional correlation between lack of ICAM-1 ex-
pression and "resistance" to CD3 mediated lysis, TNF was used which is 
known to induce ICAM-1 expression on many cell types (21). Incubation 
of IgR39 cells with 1000 U/ml recTNF for 24 h induced ICAM-1 expression 
as determined by FACS-analysis (Figure 5.2). This expression of ICAM-1 
was accompanied by a simultaneous increase in susceptibility to CD3 
mediated lysis (Figure 5.3). Definitive proof that the lack of ICAM-1 
is the critical factor in the "resistance" to CD3 mediated lysis of 
IgR39 target cells comes from anti-ICAM-1 mAb inhibition studies. 
ICAM-1 specific mAb abolished the, by TNF treatment obtained, increased 
levels of CD3 mediated lysis of IgR39 target cells (Figure 5.3). The 
level of lysis of untreated IgR39 cells was, as expected, not affected 
by anti-ICAM-1 mAb. Thus, TNF induced expression of ICAM-1 is suf-
ficient to account for the TNF induced increase in susceptibility of 
IgR39 target cells to CD3 mediated CTL lysis. 
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Figure 5.3 Anti-ICAM-1 mAb abolishes the increased susceptibility of 
TNF treated IgR39 cells to CD3 mediated lysis by TCRyo+; 
CD3+ clone WiK (panel A) or TCRo:S"'" /CD3+ clone Dll (panel 
B). 
IgR39 cells were cultured with or without 1000 U/ml 
recTNF for 24 h and TNP modified before use as target 
cells. Hetero-crosslinked anti-CD3 mAb and anti-ICAM-1 mAb 
(84 H10, dilution 1/1000 of ascites) were added simul-
taneously to the CTL effectors prior to the addition of 
target cells D, IgR39; 1111, IgR39 + anti-ICAM-1 mAb; 0, 
TNF treated IgR39 and e, TNF treated IgR39 + anti-ICAM-1 
mAb. EJT ratio was 10. 
Signaling properties of LFA-1 in CTL activation 
To examine the signaling abilities of LFA-1 in the activation of the 
lytic machinery of CTL, the effect of anti-CD18 (LFA-113) mAb on spon-
taneous and anti-CD3 mAb induced conjugate formation and cytolysis was 
tested. As shown in Table 5.1, anti-CD18 mAb inhibited spontaneous 
conjugate formation of CTL with ICAM-1+ Licr-Lon cells but minimally 
with ICAM-1- IgR39 cells. The latter suggests that IgR39 cells also 
lack sufficient expression of alternative ligands for LFA-1 (e.g. 
ICAM-2) (30). Anti-CD3 mAb containing heteroconjugated Ab enhanced the 
percent conjugates formed between CTL and tumor cells. CD18 specific 
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Table 5.1 Inhibition of conjugate formation by anti-CD18 (LFA-1S) 
mAb. 
Addition of 
heteroconjugatebl 
anti-CD3 x anti-DNP 
anti-CD3 x anti-DNP 
Anti-CD18 
mAbc) 
+ 
+ 
a> TCRyo+ effector cell: WiK. 
%conjugates between TCRyo+ CTLa> 
and TNP-target cells 
ICAM-1+(Licr-Lon) ICAM-1- (IgR39) 
34 
17 
52 
48 
23 
19 
35 
31 
bl Heteroconjugate concentration 1 pg/ml. 
c) Anti-CD18 (CLB54 ascites, 1/1000). 
d) For calculation of % conjugates see Materials and Methods. 
mAb had virtually no inhibitory effect on CD3 mediated conjugate forma-
tion of CTL to ICAM-1+ or ICAM-1- tumor cells (Table 5.1), but did in-
hibit CD3 mediated lysis of the ICAM-1+ or ICAM-1- target cells (Fig-
ure 5.4). This significant inhibitory effect of CD18 specific mAb on 
lysis contrasts with the marginal inhibitory effects on conjugate for-
mation. Anti-CD18 mAb even inhibited CD3 mediated lysis when added 
15 min after the addition of target cells, at which time conjugates 
were already formed (Figure 5.5). These findings are consistent with a 
regulatory role for LFA-1 in CD3 mediated CTL activation post CTL/ 
target cell conjugate formation. 
Anti-cD18 x anti-DNP hetero-crosslinked Ab coactivates CD3 mediated 
lysis of ICAM-1- target cells 
Experiments were designed to mimic LFA-1/ICAM-1 interactions, using 
anti-CD18 X anti-DNP hetero-crosslinked Ab. Addition of anti-CD18 x 
anti-DNP Ab-heteroconjugate increased the susceptibility of ICAM-1-
IgR39 target cells to CD3 mediated lysis by TCRyo+ CTL (Table 5.2). 
Similar results were obtained using TCR~ CTL (data not shown). The 
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Figure 5.4 Anti-CD18 mAb inhibits CD3 mediated lysis of 
cells (panel A) or ICAM-1+ Licr-Lon cells 
TCRy&+;co3+ clone WiK. 
ICAM-1- IgR39 
(panel B) by 
Target cell lysis is induced by the indicated concentra-
tion anti-CD3 mAb in the absence (solid bars) or presence 
(hatched bars) of anti-CD18 mAb (CLB54, 1/1000 of ascites). 
E/T ratio was 10. 
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Figure 5.5 Anti-CD18 mAb inhibition of CD3 mediated lysis of IgR39 
cells by TCRy&+;co3+ clone WiK. 
Table 5.2 
Anti-CD18 mAb (CLB54, 1/1000 of ascites) is added 15 min 
before (0); simultaneously with (..6..) or 15 min after (O) 
the addition of target cells to CTL and hetero-crosslinked 
anti-CD3. D Control, without anti-CD18 mAb. E/T ratio was 
10. 
Anti-CD18 X anti-DNP Ab coactivates lysis of the ICAM-r 
target celP l. 
ICAM-1 - (IgR39) ICAM-1+ (Licr-Lon) 
Ab b) 
heteroconjugates Exp.1 Exp.2 Exp.3 Exp.4 Exp.1 Exp.2 Exp.3 Exp.4 
15c) 13 
aCD18 X aDNP !~d) 37 aClassi X aDNP 16 
aCD3 X aDNP 24 11 44 29 
aCD3 X aDNP aCD18 X aDNP !~d) 31 70 56 aCD3 X aDNP aClassi X aDNP 12 40 23 
a) Effector TCRy&+/CD3+ clone: WiK. 
b) Heteroconjugate concentration aCD3 x aDNP 
aCD18 X aDNP 
aclass I x aDNP 
c) %specific lysis at an E/T ratio of 24. 
d) nt =not tested. 
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n~d) 
49 37 
!~d) 46 33 
0.1 pg/ml 
0.1 pg/ml 
0.1 pg/ml. 
11 
13 
11 
59 74 
69 76 
63 68 
susceptibility to lysis of ICAM-1+ target cells was much less affected 
(Table 5.2). Remarkably, anti-CD18 x anti-DNP Abalone also consider-
ably enhanced MHC-unrestricted lysis of ICAM-1- but not of ICAM-1+ 
target cells by TCRyo+ CTL. Control, anti-HLA Class I x anti-DNP Ab had 
no effect on MHC-unrestricted or CD3 mediated lysis. 
Discussion 
Initiation of CD3jTCR complex mediated T cell functions is believed 
to be interrelated with various accessory molecules. The transmembrane 
molecule LFA-1 is one of the most important accessory molecules. Here, 
the contribution of the LFA-1/ICAM-1 interaction to CD3/TCR complex 
mediated lysis by TCR~ and TCRyo+ CTL at different stages of the 
lytic cycle was studied. The use of hetero-crosslinked anti-CD3 x anti-
DNP Ab allows the comparison of susceptibilities to lysis of different 
tumor cell lines by an individual CTL clone. An ICAM-1- melanoma tumor 
cell line IgR39 shows a relative resistance to CD3/TCR mediated cyto-
lysis by TCR~ as well as by TCRyo+ cloned lymphocytes. The low sus-
ceptibility of IgR39 tumor cells to CD3/TCR mediated cytolysis was 
directly related to the lack of ICAM-1 expression because TNF treatment 
of ICAM-1- IgR39 cells induced ICAM-1 expression and indeed simul-
taneously increased susceptibility to CD3/TCR mediated cytolysis. More-
over, anti-ICAM-1 mAb downregulated this TNF induced, increased sus-
ceptibility to lysis, demonstrating that it was functionally due to 
upregulation of ICAM-1 and not other unknown ligands. 
The relative resistance of IgR39 cells to CD3 mediated cytolysis can 
be overcome by higher concentrations of anti-CD3 mAb. Thus an efficient 
LFA-1/ICAM-1 interaction may lower the requirement for either high 
antigen density on target cells or, alternatively, may compensate for a 
low affinity TCR on CTL by establishing a more effective CTL-target 
cell interaction. 
The interaction between CTL and target cells, resulting in target 
cell lysis, is a multistep proces (2,7). Thus the relative resistance 
of the ICAM-1- IgR39 target cells to CD3/TCR mediated lysis may reflect 
either a less efficient conjugate formation, or a decreased level of 
activation of the lytic machinery. This study shows that CTL less ef-
ficiently formed conjugates with ICAM-1- than with ICAM-1+ tumor cells. 
Hetero-crosslinked anti-CD3 mAb enhanced conjugate formation with both 
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the ICAM-1 negative and positive target cells. Addition of anti-CD18 x 
anti-DNP Ab increased spontaneous and CD3 mediated conjugate formation 
with the ICAM-1- cell line and consequently enhanced CD3jTCR mediated 
lysis of this target cell. Hetero-crosslinked anti-CD18 rnAb failed to 
enhance CD3jTCR mediated lysis of !CAM-~+ tumor cells, because it could 
not further enhance the relatively efficient conjugate formation with 
this target. Remarkably, hetero-crosslinked anti-HLA Class I did not 
enhance CD3 mediated conjugate formation with the ICAM-1- target cells 
(data not shown) and therefore did not affect CD3 mediated lysis. 
The data suggest that the relative resistance to CD3 mediated lysis 
of the ICAM-1- tumor cells is not exclusively associated with a de-
creased conjugate formation. The LFA-1/ICAM-1 interaction also appears 
to synergize with CD3/TCR mediated lysis at a postconjugate stage. 
LFA-1 specific rnAb reportedly block lysis by NK and CTL cells through 
inhibition of conjugate formation (24,39). Here we show that, although 
anti-CD18 rnAb inhibited CD3 mediated cytolysis by CTL of an ICAM-1-
tumor cells, it did not affect their conjugate formation. Anti-CD18 rnAb 
blocked CD3 mediated lysis of both reAM: or ICAM-1- target cells, even 
when added 15 min after mixing CTL and target cells at which time con-
jugates are already formed. These findings suggest that LFA-1 can 
transduce downregulatory signals postconjugate formation, although the 
possibility that the inhibitory effect of anti-CD18 rnAb is solely due 
to decreased recycling of CTL is to be formally excluded. A further 
argument in favor of a signaling function for LFA-1 comes from the 
previously reported observation that ICAM-1- IgR39 tumor cells show 
comparable susceptibility to CD2 mediated lysis as ICAM-1+ tumor cells 
(Chapter 4, 6). The relative resistance of ICAM-1- target cells to CD3, 
but not CD2, mediated lysis demonstrates that it is not merely due to a 
decreased conjugate formation ability but suggests a signaling function 
for the LFA-1- /ICAM-1 interaction. Hetero-crosslinked anti-CD18 mAb 
enhanced MHC-unrestricted lysis of the ICAM-1- target cell by TCRyo+ 
CTL but not by TCR~ CTL in two out of four experiments. Still, LFA-1 
crosslinking to the target cell per se is not sufficient to trigger the 
cytolytic machinery of TCR~ and TCRyo+ CTL because anti-LFA-1 mAb 
expressing hybridomas, crosslinking LFA-1, were not lysed by the CTL 
(40, unpublished observation). Hence, LFA-1 transduces a coactivation 
signal rather than a primary signal. Whether the functional interre-
lation between LFA-1 and the CD3/TCR complex depends on coclustering of 
these molecules as has been demonstrated for CD3jTCR and the accessory 
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molecule CD4 (41), remains to be established. 
In summary, these results demonstrate the central role of LFA-1 in 
T cell activation. The LFA-1/ICAM-1 interaction appears to be involved 
in CD3jTCR mediated lysis at two distinct stages of the lytic cycle. 
Firstly, it promotes binding of CTL to target cells and secondly, it 
delivers costimulatory signals to CD3/TCR in triggering cell mediated 
lysis. Consequently, tumor cells lacking ICAM-1 expression may escape 
lysis by CTL. The relative resistance of ICAM-1- tumor cells to lysis 
might be overcome by the induction of ICAM-1 on the tumor cell surface, 
e.g. with TNF or IFN-y (21). Also the use of anti-CD2 x anti-target Ab 
which activate CTL independently of the additional LFA-1/ICAM-1 inter-
action or the combined use of bispecific anti-CD3 x anti-target and 
anti-LFA-1 x anti-target Ab may induce efficient lysis of ICAM-1- tar-
get cells. 
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CHAPTER 6 
LFA-1/ICAM-1 INTERACTION PBOMOTES MHC-uNRESTRICTED AS WELL AS CD16 
MEDIATED CYTOLYSIS 
Introduction 
Target cell lysis by cytotoxic lymphocytes involves adhesion between 
lymphocytes and target cells followed by triggering of the lytic ma-
chinery and deli very of the lethal hit ( 1). TCRc:xtr" ;co3+ 16- T lympho-
cytes are triggered via the TCR complex upon MHC-restricted antigen 
specific recognition (2,3). On the contrary TCRyo+;co3+16+/- T 
lymphocytes and TCR-;co3-16+ NK cells exert MHC-unrestricted lysis 
via a putative receptor (4,5). Target cell recognition is preceeded by 
nonspecific interactions between adhesion molecules with ligands (6). 
Two adhesion pathways are well documented: C02 on T lymphocytes, inter-
acting with LFA-3 (C058) on target cells (7-9) and LFA-1 on T 
lymphocytes, interacting with intercellular adhesion molecule-1 
(ICAM-1, C054) on target cells (7,10,11). C02 is also involved in sig-
nal transduction upon binding to LFA-3 (12,13). 
The LFA-1 glycoprotein is a heterodimer consisting of a 180 kDa a 
chain (COlla), which is noncovalently associated with a 95 kDa ~chain 
(C018). LFA-1 is expressed on most leucocytes (6,14) and involved in 
homotypic adhesion of leucocytes (15) and heterotypic adhesion of 
lymphocytes to a variety of lymphoid and nonlymphoid cells (16,17). 
Moreover, LFA-1 up- or downregulates adhesion independent lymphocyte 
proliferation (18,19). In addition, a unique anti-COlla mAb has been 
described which induces homotypic T cell and B cell adhesion (20). 
ICAM-1 is a monomeric glycoprotein of relative molecular mass 90 kDa 
and expressed on a variety of hemopoietic as well as nonhemopoietic 
cells (21). ICAM-1 expression can be increased by inflammatory lympho-
kines (22,23) which might enhance the binding of leucocytes at inflam-
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matory sites. Functional studies have revealed that ICAM-1 is involved 
in LFA-1 dependent T cell functions such as B cell activation and T 
cell proliferation and cytolysis (24-27). The importance of the LFA-1-
/ICAM-1 interaction was further indicated by reports which showed that 
Burkitt's lymphoma cells may escape cytolysis because of their low 
expression of LFA-1, ICAM-1 and LFA-3 (28,29). We recently demonstrated 
that LFA-1/ICAM-1 interactions coactivate TCR/CD3 complex mediated 
tumor cell lysis by TCR~ as well as TCRyo+ clones (Braakman et al., 
submitted for publication). 
Here we studied the role of this LFA-1/ICAM-1 interaction in MHC-un-
restricted and anti-CD16 mAb triggered lysis. Fresh and cloned 
TCR-;co3-16+ NK cells and cloned TCRyo+;co3+16+/- T lymphocytes were 
used as effector cells; ICAM-1+ or ICAM-1- tumor cell lines were used 
as target cells. Ab-heteroconjugates, which comprised an anti-CD16 Fab2 
mAb chemically coupled to an anti-DNP Fab2 Ab were used to trigger 
lysis of TNP modified target cells (30). Results show that the LFA-1/ 
ICAM-1 interactions promote MHC-unrestricted lysis by both TCR-/CD3- NK 
as well as TCRyo+;co3+ T cells. Moreover, LFA-1/ICAM-1 interactions 
also coactivate CD16 mediated lysis. 
Materials and Methods 
Human cytotoxic clones 
The TCR- /CD3-16+ NK cell clones NK76 and NK77 were derived from a 
patient with Ty lymphocytosis (31) and clone NK472 from a patient with 
severe combined immunodeficiency. TCRyo+;co3+4-8-16+ clone 1042 was 
derived from PBL from a lung tumor patient and TCRyo/CD3+4-s-16- clone 
WiK was a generous gift from Dr. D.A. Hafler (Harvard Medical School, 
Boston, USA) (32). All clones were generated by limiting dilution and 
maintained in culture as previously described (33). 
TCR-/CD3-16+ NK cell enriched PBL 
Fresh PBL from a healthy donor were depleted for adherent cells by 
1-h incubation on plastic at 37°C. The nonadherent lymphocyte fraction 
was incubated with SRBC at 29°C for 60 min to form rosettes. The E29° 
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non rosette forming lymphocyte fraction contained up to 25% CD16+ 
lymphocytes as determined by irnmunophenotypic analysis using the 
anti-CD16 mAb B73.1 (34). 
Cell lines 
Tumor cell lines used in this study were: IgR37, IgR39 and Mel2A, 
three melanoma derived cell lines; T24, a bladder carcinoma cell line; 
u-937, a promonocytic cell line; K562, an erythromyeloid cell line; APD 
and BSM, two Epstein-Barr virus transformed B cell lines; Daudi, a 
Burkitt's lymphoma derived cell line; Licr-Lon, a leukemic plasma cell 
line, and Molt-4, a T cell leukemia. Cell lines were cultured in RPM! 
buffered with bicarbonate (2 gjl) and Hepes (4.8 g/1) and supplemented 
with 10% heat-inactivated fetal calf serum (FCS), 4 mM glutamine and 
100 IU/ml penicillin and streptomycin. The melanoma and bladder derived 
cell lines growing in monolayer cultures were harvested by tryp-
sinization. Alternatively a PBS/5 mM ED~ solution was used. 
Reagents and mAb 
Human recombinant (rec) TNF (Cetus Corporation Lot i NP200B, Emery-
ville, CA, USA) and human reciFN-y (a gift from Dr. P.H. van der Meide, 
Primate Center TNO, Rijswijk, The Netherlands) were tested for their 
ability to increase the cell surface expression of ICAM-1 on various 
tumor cell lines as described (23). The tumor cells were cultured at 
2xl05 cells/ml with medium, 25 U/ml reciFN-y or 1000 U/ml recTNF for 
24 h. mAb used for irnmunophenotypic analysis were: anti-CD18 (LFA-113) 
mAb CLB54, kindly provided by Dr. R.A.W. van Lier (Central Laboratory 
for Blood Transfusion Service, Amsterdam, The Netherlands) (35); 
anti-COlla (LFA-la) mAb TSl/22 and anti-LFA-3 mAb TS2/9, generous gifts 
from Dr. A.M. Krensky (Stanford University Medical Center, Stanford, 
CA, USA) (14); anti-ICAM-1 mAb 84Hl0 (11) and anti-CD16 mAb 3G8 (36), 
which was unreactive with the TCRy&+ clones. Labeling procedures were 
performed as described elsewhere (31) and cells were analysed by flow 
cytometry on a FACScan (Becton Dickinson, Mountain View, CA, USA). 
97 
Chemical crosslinking of Ab 
Fab2 fragments were prepared from affinity chromatography purified 
rabbit anti-2,4 dinitrophenyl (DNP) Ab and anti-CD16 mAb (3G8) by 
papain digestion and did not contain any intact antibody as judged by 
SDS page (30). Bispecific Ab-heteroconjugates of 3G8 Fab2 x anti-DNP 
Fab2 were prepared using the crosslinking reagent dimethyl suberimidate 
(OMS) (30). 
Lymphocyte-tumor cell conjugate formation assay 
Tumor cells (5x106 ) and lymphocytes 5x106 were intracellularly 
labeled with 0.05 pg/ml carboxy fluorescein diacetate (CFDA) or 
100 pg/ml hydroethidine (HE) respectively, for 30 min at 37°C in a 
volume of 2 ml. Both tumor cells and lymphocytes were washed twice in 
RPM! 1640jHepes plus 10% FCS and concentrated to 107 cellsjml. Blocking 
of conjugate formation was performed by preincubation (15 min) of 
lymphocytes with anti-CD18 mAb. Equal numbers of labeled tumor cells 
and lymphocytes were mixed, in a final volume of 100 pl, and centri-
fuged in a serofuge (5 sec). Subsequently, the mixture was incubated at 
21°C for 10 min. Conjugate formation was stopped by the addition of 
1 ml ice-cold PBS/1% BSA. Cells were gently resuspended and immediately 
analysed on a FACScan. The percentage of lymphocytes that formed conju-
gates with tumor cells was calculated by dividing the percentage of 
events emitting both red (HE) and green (CFDA) fluorescence by the 
total percentage of events emitting red fluorescence. 
cytotoxicity assay 
Cytotoxic activity was measured in a standard 3-h 51 Cr release assay 
(31). In short, varying numbers of lymphocytes were seeded in tripli-
cate in 96 well round bottomed microtiter plates (Greiner Labor Tech-
nik, Phidelsheim, FRG). To study anti-CD16 x anti-DNP Ab-heteroconju-
gate induced lysis, tumor cells were incubated with 0.3 mM trinitro-
benzene sulfonate (TNP) for 15 min at 37°C, followed by washing. Ab-
heteroconjugates were added to the lymphocytes 30 min before addition 
of 51 Cr-labeled TNP-tumor cells. Cytotoxicity was blocked by anti-CD18 
mAb, added 30 min prior to addition of the TNP-tumor cells. The stan-
dard error of the mean percentage lysis never exceeded 6% and was omit-
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ted for clarity of presentation. 
Results 
IgR37 and IgR39 melanoma cells are relatively resistant to MaC-unre-
stricted or anti-cD16 :mAb triggered lysis 
Histologically distinct tumor cell lines were tested for their sus-
ceptibility to MHC-unrestricted lysis by cloned TCR-;cn3-16+ lympho-
cytes. Most tumor cell lines were susceptible to MHC-unrestricted 
lysis, but two melanoma derived cell lines IgR37 and IgR39 were rela-
tively resistant to lysis by TCR- NK cell clones (Figure 6.1). Tumor 
cell lines were also coated with TNP and tested for their suscepti-
bility to anti-CD16 mAb triggered lysis using anti-CD16 x anti-DNP Ab 
heteroconjugate. IgR37 and IgR39 melanoma cells were also relatively 
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Figure 6.1 IgR37 and IgR39 melanoma are relatively resistant to 
MHC-unrestricted 1 ysis by TCR-;cn3-16 NK cell clones: NK76 
(A), NK77 (e) and NK472 ( +). E/T ratio was 12. 
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resistant to CD16 mediated lysis (Figure 6.2). This was found for both 
NK cell enriched PBL and cloned TCFr/CD3-16+ NK cells showing that the 
relative resistance to lysis was not donor dependent. The relative 
resistance of IgR37 and IgR39 to CD16 mediated lysis was not caused by 
the TNP-coating of the tumor cells, because both melanoma derived cell 
lines were efficiently lysed using an anti-CD2 x anti-DNP Ab-heterocon-
jugate (37). 
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Figure 6.2 IgR37 and IgR39 melanoma show relative resistance to 
anti-CD16 mAb triggered lysis by CD16+ NK cell enriched PBL 
(panel A) or TCR-/CD3-16+ NK cell clone 472 (panel B). 
TNP-APD ( 8 ) , TNP-Licr-Lon ( +), TNP-IgR37 ( 1111 ) and 
TNP-IgR39 (~) were tested for their susceptibility to 
anti-CD16 x anti-DNP Ab-heteroconjugate induced lysis at 
E/T ratio 21 (panel A) or 12 (panel B). 
IgR39 and IgR37 melanoma cells express little or no ICAM-1: upregu-
lation of ICAM-1 expression by 'lNF or IFN-y 
The differential susceptibility to lysis of distinct tumor cell 
lines may be due to differential levels of expression of particular 
target cell surface ligands involved in effector/target cell inter-
action. Therefore, LFA-3 and ICAM-1 expression on the tumor cell sur-
face were quantified by FACS analysis. Most histogenetically distinct 
tumor cell lines expressed high levels of ICAM-1 and LFA-3 (100% posi-
tive cells). However, the relatively lysis resistant melanoma cell 
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lines IgR39 and IgR37 expressed either little or no ICAM-1 (s 5% or 25% 
ICAM-1+ cells, respectively). A third melanoma cell line (Mel2A), nor-
mally expressed ICAM-1 and thus the lack or low expression of ICAM-1 is 
not melanoma related. TNP modification of tumor cell lines did neither 
affect LFA-3 nor ICAM-1 expression (data not shown). 
It was tempting to speculate that lack of ICAM-1 expression was 
functionally related to the low susceptibility to MHC-unrestricted or 
anti-CD16 mAb triggered lysis. Thus, upregulation of ICAM-1 expression 
should increase the level of lysis. Induction or enhancement of cell 
surface expression of ICAM-1 by IgR37 and IgR39 was achieved by IFN-y 
and TNF (Figure 6.3). Both lymphokines induced comparable levels of 
ICAM-1 
LFA-3 
HLA class I 
IgR 39 
melanoma 
IgR37 
melanoma 
fluorescence intensity {log scale) 
Licr-Lon 
B cell leukemia 
Figure 6.3 TNF and IFN-y upregulate ICAM-1 expression on ICAM-1- tumor 
cells. 
Tumor cells were cultured with 1000 U/ml human recTNF 
(--), 25 U/ml reciF'ij-y (--) or medium (- -) for 24 h 
and stained with mAb. Negative controls( .••• ) were stained 
with FITC-conjugated goat anti-mouse Ab serum (dilution 
1/40) (Nordic, Tilburg, The Netherlands) and gave compar-
able results after the various incubations. 
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ICAM-1 on the ICAM-1- cell lines. By contrast, no further enhancement 
of ICAM-1 expression was observed on the ICAM-1+ cell lines. The 
expression of LFA-3 or HLA Class I was virtually not affected by TNF or 
IFN-y. TNF was used in further experiments to increase ICAM-1 ex-
pression. 
upregulation of ICAK-1 expression on tumor cells reconstitutes suscep-
tibility to MBC-unrestricted or anti-cD16 mAh triggered lysis 
Subsequently, we addressed the question whether induction of ICAM-1 
expression by target cells simultaneously enhanced their formation of 
conjugates with lymphocytes and their susceptibility to MHC-unrestric-
ted or anti-CD16 mAb triggered lysis. TNF-induced ICAM-1 expression by 
tumor cells coincided with an increased percentage of conjugates be-
tween TCR-/CD3-16+ NK cell clones and tumor cells (Table 6.1). Simul-
taneously, the level of MHC-unrestricted lysis by TCFr or TCRyo+ clones 
as well as the level of anti-CD16 mAb triggered lysis by TCR- clones 
was increased (Table 6.2). This increased cytotoxicity was inhibited by 
the anti-ICAM-1 mAb 84Hl0 (Figure 6.4), demonstrating that this in-
creased susceptibility to lysis was proportionally related to the 
ICAM-1 expression on the tumor cells. 
Table 6.1 Upregulation of ICAM-1 expression on ICAM-1- tumor cells 
enhances conjugate formation. 
% Effector cell-tumor cell conjugates 
ICAM-1- ICAM-1± ICAM-1+ 
melanoma melanoma B cell leukemia 
(IgR39) (IgR37) (Licr-Lon) 
Effector cells TNF'"-) 
TCR- NK clones + + + 
NK472 7 16 22 17 
NK 77 17 26 35 45 30 24 
NK 76 9 15 20 47 14 18 
a) Incubated with 1000 U/ml recTNF for 24 h. 
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Table 6.2 Upregulation of ICAM-1 expression on ICAM-1- tumor cells 
enhances MHC-unrestricted or anti-CD16 mAb triggered lysis. 
% lysis of TNP-tumor cells 
ICAM-1+ ICAM-r 
Effector Addition B cell leukemia melanoma 
cells (Licr-Lon) (IgR39) 
TCR- /CD3-16+ Anti-CD16 x anti-DNP ~) 
clonesa) Ab-heteroconjugate 
ng/ml + + 
NK472 0 34 31 0 6 
60 82 77 13 27 
250 93 86 39 53 
NK76 0 27 28 2 9 
60 57 56 4 13 
250 69 69 7 22 
NK77 0 30 35 9 19 
250 69 73 23 35 
a) NK472 and NK76 were tested at an E/T ratio of 12, NK77 at 24. 
b) Incubated with 1000 U/ml recTNF for 24 h. 
LFA-1 has a postconjugate regulatory role in cytolysis 
The LFA-1 molecule, in addition to its adhesion function, may also 
play a role in transducing regulatory signals. Therefore, we studied 
the effect of anti-CD18 (LFA-1~) mAb in conjugate formation and cyto-
toxicity experiments. In agreement with earlier reports (14,38,39), 
MHC-unrestricted lysis of ICAM-1+ tumor cells was inhibited by 
anti-CD18 mAb (Figure 6.5), due to inhibition of conjugate formation 
(Table 6.3). Importantly, whereas anti-CD18 mAb inhibited MHC-unre-
stricted lysis of ICAM-1- tumor cells, it did not affect their forma-
tion of conjugates with lymphocytes (Table 6.3). 
103 
%lysis 
50 
40 
30 
20 
10 
0 
0 60 250 
anti-CD16 x anti-DNP (ng/mll 
Figure 6.4 Anti-ICAM-1 mAb blocks the increased susceptibility of TNF 
treated IgR39 cells to MHC-unrestricted or anti-CD16 mAb 
triggered lysis. 
ICAM-1- IgR39 
1000 U/ml recTNF 
cells were incubated with medium (D) or 
( 0) for 24 h. Anti-CD16 mAb triggered 
lysis by the TCR-/CD3-16+ clone NK76 was blocked with 
anti-ICAM-1 mAb, preincubated for 15 min with target cells. 
E/T ratio was 12. B= anti-ICAM-1 mAb (1/1000 dilution of 
ascites) + IgR39, e = anti-ICAM-1 mAb + TNF-IgR39. 
40 
30 
" 
"' ill 
-e 
"-~ 20 
0 
~ g. 
t'- 10 
ICAM-1" 
(lgR 39) 
TCR" TCR" TCRyo+ TCRyO+ 
(NK77) (NK76) (WiK) (1 042) 
ICAM-1+ 
(Licr-Lon) 
TCR" TCR" TCR]O+ TCRya+ 
(NK77) (NK76) (WiK) (1042) 
Figure 6.5 Anti-CD18 mAb inhibits MHC-unrestricted lysis of ICAM-1+ or 
ICAM-1- tumor cells by TCR- NK or TCRy~+ T cell clones. 
E/T ratio was 24. ji!'.::!/i:H medium, - anti-CD18 mAb 
(1/400 dilution of ascites). 
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Table 6.3 Anti-CD18 mAb blocks conjugate formation with ICAM-1+, but 
not with ICAM-1- tumor cells. 
% Conjugate formation 
Tumor cells 
Lymphocyte Anti-CD18 ICAM-1+ ICAM-r 
clones mAba) B cell leukemia melanoma 
(Licr-Lon) (IgR39) 
TCRyo+;co3+16± 18 8 
(1042) + 3 8 
TCRyo+ /CD3+ 16- 28 18 
(WiK) + 16 17 
TCR-/CD3-16+ 22 13 
(NK76) + 18 14 
TCR- /CD3-16+ 30 17 
(NK77) + 21 17 
a) Anti-CD18 mAb was added at a final concentration of 1/1000 dilution 
of ascites. 
Discussion 
In this Chapter we show that the LFA-1/ICAM-1 interaction coacti-
vates MHC-unrestricted lysis by TCR- as well as TCRyo+ cloned lympho-
cytes. Anti-CD16 mAb triggered lysis by TCR-/CD3-16+ lymphocyte clones 
is also regulated by LFA-1/ICAM-1 interactions. The latter was demon-
strated with anti-CD16 x anti-DNP Ab-heteroconjugate using TNP-coated 
tumor target cells. This approach allows to compare tumor cell suscep-
tibilities to mAb triggered lysis by individual TCRC clones. 
The tumor cell lines IgR37 and IgR39 appeared to be relatively re-
sistant to MHC-unrestricted or CD16 mediated lysis by TCR- NK cells. 
IgR39 melanoma cells, but not IgR37, were also ~elatively resistant to 
MHC-unrestricted lysis by TCRyo+ T cell clones, as reported earlier 
(4). The relative resistance of the melanoma cells to lysis was not due 
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to trypsinization of the in monolayer cultures growing melanoma cell 
lines, because similar results were obtained when a PBS/5 mM ED~ sol-
ution was used to make a single cell suspension. Moreover, tryp-
sinization of the ICAM-1+ cell lines T24, Mel 2A, Licr-Lon or Molt-4 
did not affect the expression of ICAM-1 nor their susceptibility to 
lysis. The relative resistance to MHC-unrestricted or anti-CD16 mAb 
triggered lysis correlated with the lack of ICAM-1 expression on IgR37 
and IgR39, because induction of tumor cell surface ICAM-1 expression by 
TNF reconstituted susceptibility to MHC-unrestricted or C016 mediated 
lysis. 
TNF treatment of ICAM-1+ cell lines did not affect ICAM-1 expression 
nor their susceptibility to MHC-unrestricted or anti-C016 mAb triggered 
lysis. Definite proof that this increased susceptibility to lysis was 
due to upregulation of ICAM-1 on the tumor cells, comes from ICAM-1 
specific mAb inhibition studies. Anti-ICAM-1 mAb significantly in-
hibited MHC-unrestricted and CD16 mediated lysis by TCR- NK clones. 
The up- or downregulatory role of LFA-1 in cytolysis depends on the 
structural nature of the stimulus to LFA-1. Crosslinking of LFA-1 
through interaction with ICAM-1 on the target cells resulted in en-
hancement of MHC-unrestricted or anti-C016 mAb triggered lysis. Mimick-
ing of the LFA-1/ICAM-1 interaction by anti-C018 x anti-DNP Ab-hetero-
conjugates promoted MHC-unrestricted or anti-CD3 mAb triggered lysis by 
TCR~ as well as TCRy&+ clones (Braakman et al., submitted for publi-
cation). However, crosslinking of LFA-1 per se did not activate the 
cytolytic machinery, because anti-COlla or anti-C018 mAb producing 
hybridomas were not lysed by fresh or clones TCR- or TCRy&+ cells (41, 
unpublished observations). Thus crosslinking of LFA-1 via ICAM-1 or mAb 
delivers a coactivation signal for MHC-unrestricted or anti-C016 mAb 
triggered lysis. 
By contrast, soluble anti-C018 or COlla mAb inhibit both CTL and NK 
cell lysis (14,38,39). It was shown that this inhibition was due to 
inhibition of antigen-nonspecific conjugate formation (40). Here, we 
shaw that anti-C018 mAb blocked MHC-unrestricted lysis of ICAM-1+ or 
ICAMI tumor cells. However, anti-C018 mAb only inhibited formation of 
conjugates using ICAM-1+ target cells. These data demonstrate a post-
conjugate regulatory role of LFA-1 in MHC-unrestricted as well as CD16 
mediated lysis. 
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In conclusion, LFA-1/ICAM-1 interactions determine target cell sus-
ceptibility to lyis. ICAM-1- tumor cells or viral infected cells may 
therefore escape the antigen specific and MHC-unrestricted immune sur-
veillance as suggested earlier (28,29) and shown here. Bifunctional Ab 
are powerful tools for the induction of target cell lysis (30,37,43) 
and are already applied in immunotherapy protocols (42). However, as we 
demonstrate here and elsewhere (Braakman et al., submitted for publi-
cation), LFA-1/ICAM-1 interactions may also regulate bifunctional Ab 
triggered cytolysis. This might be overcome by induction of ICAM-1 on 
target cells (as was shown here), or by using other bifunctional Ab, 
e.g. comprising anti-CD2 mAb (37). 
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CHAPTER 7 
The host immune system-tumor relationship can be viewed as a deli-
cate balance which is influenced by internal as well as external sig-
nals. The immune system is designed to recognize and destroy tumor 
cells in the earliest possible stage. However, a tumor may break 
through the defense provided by the immune system. This Chapter deals 
with the host immune system-tumor relationship, the mechanisms which 
may lead to escape of tumor cells from immune surveillance, and dis-
cusses several approaches to immunotherapy of cancer which are pres-
ently used or open for experimentation in the future. 
Tumors can be induced by chemical substances, irradiation, viruses 
or arise spontaneously. It was first proposed by Ehrlich (1) and later 
substantiated by others (2,3), that cells which are antigenically suf-
ficiently distinct from normal cells are recognized by components of 
the immune system and subsequently eliminated (immune surveillance 
theory). The effectiveness of a persons in vivo cellular immune re-
sponse against tumor cells depends on the number of cytotoxic effector 
cells and antibodies that can be recruited, their ability to recognize 
and lyse tumor cells and the persons tumor load. Evidence has emerged 
from animal models that an intact immune response can be effective in 
the elimination of distinct histological types of tumors (4,5). 
'l'lmlor cell escape from ilmnme surveillance 
Several mechanisms can be envisaged which may cause escape of tumor 
cells from immune surveillance. First, tumors may be insufficiently 
immunogenic to elicit an immune response. Secondly, tumor cells may 
survive and proliferate because of a deficient immune response. 
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Tumor escape may occur because tumor cells lack antigens which dis-
criminate them from normal cells. In some cases the transformation of 
normal cells to malignant cells is due to the uncontrolled expression 
of normal proteins. Therefore, these tumors do not express nee-anti-
gens, but only differ from normal cells in their level of expression of 
these antigens. Alternatively, tumor cells may express nee-antigens, 
but their density is too low to be immunogenic in vivo. Escape from 
immune surveillance may also be caused by shedding of nee-antigens from 
the cell surface (6). Shedding of surface antigens from both normal and 
neoplastic cells was demonstrated by Cone et al (7). 
Tumor cells expressing nee-antigens may still be resistant to lysis 
by cytotoxic lymphocytes because they do not.express sufficient levels 
of ligands for accessory molecules on the immune cells. Accessory mol-
ecules on lymphocytes (activation sites and/or adhesion molecules) play 
an important role in lymphocyte activation (as shown in Chapter 4, 5 
and 6). These accessory molecules not only increase the overall avidity 
of lymphocyte-tumor cell interactions, but also transduce signals that 
facilitate lymphocyte activation. The overall avidity is extremely 
important when tumor cell-associated antigens are expressed at low 
densities (see above). The crucial role of accessory molecule-ligand 
interactions in tumor cell resistance to lysis was demonstrated here 
and suggested by Gregory et al. (8). LFA-1, LFA-3 and ICAM-1 negative 
Burkitt's lymphoma derived cells were resistant to lysis by specific 
CTL. Expression of LFA-1, LFA-3 and ICAM-1 was induced on the Burkitt's 
lymphoma cells during culture, which coincided with an increased sus-
ceptibility to lysis. We obtained similar data with ICAM-1- melanoma 
derived cells that were relatively resistant to cytolysis by TCR~ 
CTL, TCRyo+ CTL as well as TCR- NK cells. Induction of ICAM-1 expres-
sion on the melanoma cells by TNF or IFN-y, increased susceptibility to 
lysis by cytotoxic lymphocytes. Conclusive evidence that indeed LFA-1/ 
ICAM-1 interactions were critical for susceptibility to lysis by NK 
cells and CTL came from inhibition studies on lysis using anti-ICAM-1 
mAb (9,10, Chapter 5 and 6). Thus, the antigenic make-up of a tumor 
cell critically codetermines its susceptibility to lysis. 
Another cause for the development of a tumor out of a limited number 
of transformed cells may be a deficiency in the immune system. A number 
of studies has clearly demonstrated an association between the potency 
of the immune system and tumor development. The tumor incidence in 
immunodeficient individuals, e.g. patients suffering from a variety of 
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hereditary immunodeficiencies, is increased (11). Another well known 
example is the occurence of Non-Hodgkin's lymphoma or Karposi sarcoma 
in acquired immunodeficiency syndrome (AIDS) (12,13). Kidney graft 
recipients who received prolonged immunosuppressive treatment are 
highly sensitive to viral infections and tumor development (14,15). It 
is generally accepted that the increased incidence of tumors in elderly 
people is related to their impaired immune responsiveness. 
In addition, local immune disfunction may be induced by tumor cells, 
subset(s) of tumor infiltrating lymphocytes (TIL) or both, through 
immunosuppressive mechanisms. Tumor cells may either directly suppress 
antitumor activity via production of factors which act on cytotoxic 
lymphocytes, or activate lymphocytes with suppressor activity. Instead, 
the partial development of immune disfunction to e.g. viral associated 
tumor antigens in a long infected host may be caused by tolerance. The 
reduction of the in vitro proliferative capacity of precursor {p)-CTL 
in TIL as compared to pCTL from PBL of patients or healthy donors, 
is supposedly due to immunosuppressive mechanisms exerted by the tumor 
(Chapter 3). 
Immunotherapy of tumors 
Having summarized a number of parameters involved in tumor cell 
lysis, the question is: how can the present knowledge be applied to 
restore the distorted balance between the host immune system and the 
established tumor. Various treatment modalities are applied, i.e. sur-
gery, chemotherapy, radiotherapy and combinations thereof. The rapid 
developments in the fields of immunology and recombinant D~ technology 
have provided new strategies for therapy, based on manipulation of the 
patients own immune system. Most initial approaches to tumor-immuno-
therapy attempted active specific immunisation. Active specific immu-
nisation is a procedure in which tumor cells from the patient are com--
bined with nonspecific immunostimulants, such as Bacillus calmette-
Guerin (BCG) or Corynebacterium parvum, to develop an antitumor vac-
cine. Such a vaccine may enhance the immunogenicity of the tumor cell 
antigens andjor create new epitopes. This may lead to an increased 
immune response against otherwise weakly immunogenic tumors (16,17). 
Other strategies have been applied, based on the activation of the 
immune system in vivo. Administration of biological response modifiers 
(BRM) such as interleukins, or interferons, have been succesfully used 
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in the treatment of tumors (18-22). Because administration of high 
doses of interleukin 2 (IL2) causes significant toxicity, immune cells 
were activated ex vivo with IL2. Both PBL and TIL derived from 
patients were used. TIL were believed to be more "specific" for the 
tumor from which they were derived and thus more effective in the 
treatment of cancers. This form of adoptive immunotherapy (reviewed in 
23) has yielded encouraging results, especially in patients with immu-
nogenic tumors, such as melanoma and renal cell carcinoma (24,25). 
Melanomas may express a variety of ~, as reflected by the generation 
of tumor specific oligo clonal TCR~/CD3+ CTL which recognize distinct 
antigens on the melanoma cell (Lotze, Mitchell, personal communi-
cation). In patients, however, the fraction of immune cells responding 
to melanoma and other immunogenic tumors is apparently insufficient. 
The use of IL2 activated lymphocytes, together with continuous IL2 
infusion, involves lymphocytes of which only 2-5% are endowed with 
anti-tumor cytolytic activity. We and others therefore stated to use 
bispecific mAb targeted lymphocytes for the selective attack of tumor 
cells, because T cells (approximately 60% of the lymphocyte population) 
are activated by anti-CD3 x anti-tumor mAb (26-30). Consequently, a 
large proportion of the adoptively transferred activated lymphocytes 
can then be mobilized to attack tumor cells. The mechanisms of bi-
specific mAb induced lysis are described in detail in Chapter 1, 4, 5, 
and 6. The use of these rnAb-retargeted lymphocytes will hopefully 
improve their homing into the tumor and elicit a localized immune net-
work response at the tumor site. This will not only result in the 
induction of cytolytic activity but also in lymphokine production. 
Bispecific mAb targeted lymphocytes may also attack tumors which lack 
the expression of ligands for accessory molecules (Chapter 5 and 6). 
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The studies presented in this thesis were initiated to define a 
rationale for the immunotherapy of cancer using cytotoxic lymphocytes 
in combination with bispecific mAb. 
The major subsets of cytotoxic lymphocytes, TCR- NK cells, TCRcxtr" 
CTL and TCRyo+ CTL are described in Chapter 1. These lymphocyte subsets 
differ in their surface receptor(s) for target cell recognition, 
expression of accessory molecules and type(s) of cytotoxic activities 
which they display. For instance lytic activity by TCRo:fj'" CTL is 
MHC-restricted, whereas NK cell activity is MHC-unrestricted. 
CTL display both types of activities. 
A short overview of the best known accessory molecules expressed on 
NK cells or CTL and their ligands expressed on target cells is also 
presented in Chapter 1. The role of accessory molecules in lympho-
cyte-target cell adhesion and in lymphocyte activation is discussed, as 
well as the mechanisms through which these processes may occur. 
In vitro studies on distinct subsets of lymphocytes require large 
numbers of pure (cloned) cells. Therefore culture conditions were 
established that allow the preferential and rapid expansion of either 
TCR- NK cells or TCR+ lymphocytes, or the nonselective outgrowth of 
both subsets from PBL of healthy donors (Chapter 2). Optimal prolifer-
ation of TCR- NK cells was obtained using a combination of irradiated 
allogeneic PBL and irradiated Epstein Barr virus (EBV) transformed 
lymphoblastoid B cell lines (B-LCL) plus interleukin 2 (IL2). Addition 
of 1 pg/ml of the lectin leucoagglutinin to the culture medium induced 
a preferential outgrowth of TCR: T lymphocytes. Although the proportion 
of TCR-NK cells was decreased to 5% or less, still a 2000-fold multi-
plication of TCR- NK cells was obtained at day 13. Without leucoag-
glutinin a 1000-fold increase of about 70% pure TCR- NK cells was 
obtained at day 13. 
Under limiting dilution conditions the majority of the clones gener-
ated was TCRcxtr" /CD4+. TCRyo+ clones were occasionally obtained, and 
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could be maintained in culture for several months. Although the life-
span of most TCR- NK cell clones is restricted to about 4 weeks, a 
panel of NK clones had a life-span of 2-3 months. 
Chapter 3 deals with the subset composition and cytotoxic features 
of PBL and TIL derived from lung tumor patients. TIL, but not PBL, from 
lung tumor patients have lower proportions of TCR- NK cells and exert 
little or no NK or ADCC activity as compared to PBL from healthy do-
nors. Upon in vitro culture using the conditions for selective expan-
sion described in Chapter 2, the TCR- enriched bulk cultures displayed 
high levels of NK and ADCC activity. Cloning of PBL and TIL in limiting 
dilution demonstrated a reduced proliferative capacity of precursor CTL 
in TIL, but cytotoxic activity of the few established clones was com-
parable to that of PBL clones. 
The requirements for activation of the lytic machinery of cytotoxic 
lymphocyte subsets through CD2 were examined, using bispecific Ab-
heteroconjugates containing anti-CD2 mAb crosslinked to ant1-DNP and 
TNP coated target cells (Chapter 4), Contrary to the CD2 activation 
requirements in TCR<Xj3"'" CTL clones, cytotoxic activity in TCRy~+ CTL 
elopes and TCR- NK cell clones can be induced by heteroconjugates con-
taining a single anti-CD2 (anti-Tl1.1) mAb. Activation of TCRy~+ cells 
via CD2 is independent of Ab-heteroconjugate binding to CD16 (FcyRIII) 
since Ab-heteroconjugates prepared from Fab fragments induced equal 
levels of cytolysis. Moreover, anti-CD16 mAb did not inhibit triggering 
via CD2 in TCRy~+ CTL. In TCR- NK cells, however, induction of cyto-
toxicity via CD2 is co-dependent on interplay with CD16. Anti-CD3 mAb 
blocked the anti-CD2 x anti-DNP Ab-heteroconjugate induced cytotoxicity 
of TCRy~+ cells, indicating a functional linkage between CD2 and CD3 on 
these cells. It was concluded that induction of lysis via CD2 shows 
qualitatively distinct activation requirements in TCR- NK cells, TCR<Xj3"'" 
and TCRy~+ CTL. 
The major activation pathway of T cells is via the TCR/CD3 complex, 
which is functionally interrelated with various accessory molecules. 
The contribution of the LFA-1/ICAM-1 interaction to CD3jTCR mediated 
lysis by TCR<Xj3"'" or TCRy~+ CTL is described in Chapter 5. ICAM-1+ or 
ICAM-1- tumor cell lines were used as target cells. Anti-CD3 and 
anti-CD18 (LFA-1~) containing hetero-crosslinked mAb were used to 
bridge CTL and target cells and to activate CTL. The ICAM-1- melanoma 
derived cell line Ig~39 appeared relatively resistant to CD3 mediated 
lysis by both TCR<Xj3"'" and TCRy~+ CTL, when compared with ICAM-1+ cell 
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lines. Induction of ICAM-1 expression on the membrane of IgR39 cells by 
TNF rendered these cells more susceptible to CD3 mediated lysis. 
Anti-ICAM-1 mAb inhibited this enhanced susceptibility to lysis, demon-
strating that the induction of ICAM-1 was the critical factor in the 
TNF-induced increase in susceptibility to lysis of IgR39 cells. 
CTL formed less efficient conjugates with the ICAM-1- cells as com-
pared to ICAM-1+ cells. Spontaneous and CD3-induced conjugate formation 
as well as CD3 mediated lysis of ICAM-1- tumor cells by CTL were en~ 
hanced by addition of anti-CD18 containing hetero-crosslinked mAb. This 
Ab-heteroconjugate mimicks LFA-1/ICAM-1 interactions between CTL and 
target cells. Soluble (noncrosslinked) anti-CD18 mAb inhibited CD3 
mediated lysis of ICAM-1- target cells by CTL, without affecting their 
conjugate formation. Anti-CD18 mAb, when added postconjugate formation, 
still inhibited lysis of both ICAM-1+ and ICAM-1- tumor cells. These 
findings suggest that the LFA-1/ICAM-1 interactions coactivate CD3/TCR 
mediated lysis by CTL on the one hand through enhanced CTL-target cell 
binding and on the other also through the delivery of postconjugate 
CD3-costimulatory signals. 
Because TCR- NK cells lack the CD3/TCR signal transduction pathway, 
the question arose whether LFA-1/ICAM-1 interactions also affect tumor 
cell susceptibility to MHC-unrestricted lysis by TCR- NK (Chapter 6). 
Moreover, the role of LFA-1/ICAM-1 interactions on lysis by TCR- NK 
cells triggered via anti-CD16 mAb was investigated. Two melanoma de-
rived cell lines, which express little or ·no ICAM-1, were relatively 
resistant to MHC-unrestricted lysis, as well as to anti-CD16 mAb trig-
gered lysis by fresh or cloned TCR- NK cells. The ICAM-1- melanoma 
cells appeared also relatively resistant to MHC-unrestricted lysis by 
TCRy&+ clones. TNF induced ICAM-1 expression on ICAM-1- tumor cells, 
and thereby increased susceptibility of melanoma ~ells to MHC-unre-
stricted or to anti-CD16 mAb triggered lysis. Thi~ enhanced suscepti-
bility to lysis was decreased again by anti-ICAM-1 mAb. These data dem-
onstrate that LFA-1/ICAM-1 interactions are functionally and posi-
tively related to susceptibility to MHC-unrestricted and CD16 mediated 
cytolysis of tumor cells. Anti-CD18 mAb inhibited MHC-unrestricted as 
well as anti-CD16 mAb triggered lysis of ICAM-1+ and ICAM-1- tumor 
cells. Anti-CD18 mAb expectedly blocked the formation of conjugates 
with ICAM-1+ target cells. In spite of the inhibition of lysis, 
anti-CD18 mAb did not block formation of conjugates using ICAM-1- tar-
get cells. Thus LFA-1 also plays a ~conjugate regulatory role in 
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MHC-unrestricted as well as anti-CD16 mAb triggered lysis. 
In the last part of this thesis (Chapter 7) a number of parameters 
which determine tumor cell lysis in vivo are discussed. 
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De in dit proefschrift gepresenteerde studies werden gestart om een 
rationale te definieren voor immuuntherapie van kanker met behulp van 
cytotoxische lymfocyten in combinatie met bispecifieke rnAb. Cyto-
toxische lymfocyten vormen de laatste verbinding in een keten van cel-
lulaire interakties van het immuunsysteem. Zij zijn onder andere in 
staat tumorcellen te lyseren. 
De voornaamste typen van cytotoxische lymfocyten, TCR- rrK cellen, 
TCR~ CTL en TCRyo+ CTL zijn beschreven in Hoofdstuk 1. Deze lymfocy-
ten subpopulaties verschillen in hun membraanreceptor(en) voor herken-
ning van tumorcellen en membraanexpressie van zogenaamde helper molecu-
len. Tevens verschillen deze subpopulaties in type(n) van cytotoxische 
aktiviteiten. Lytische aktiviteit van TCR~~ CTL is MHC-gerestricteerd, 
dat wil zeggen dat antigeen herkend wordt in combinatie met MHC deter-
minanten. TCR- NK celaktiviteit daarentegen is MHC niet-gerestricteerd. 
TCRyo+ CTL vertonen beide typen van aktiviteiten. In Hoofdstuk 1 wordt 
bovendien een kort overzicht gegeven van de meest bekende helper mole-
culen die geexpresseerd worden op NK cellen of CTL en hun liganden die 
geexpresseerd worden op tumorcellen. De rol van helper moleculen in 
lymfocytjtumorceladhesie en in aktivatie van lymfocyten wordt bediscus-
sieerd, alsmede de mechanismen via welke deze processen plaatsvinden. 
In vitro studies aan gescheiden subpopulaties van lymfocyten verei-
sen grote aantallen van gezuiverde (gekloneerde) cellen. Daarom werden 
kweekcondities vastgesteld voor de preferentiele en snelle vermeerde-
ring van 6f TCR+ lymfocyten 6f TCR- NK cellen. Tevens werden condities 
bepaald voor de niet-selectieve uitgroei van beide subpopulaties uit 
perifeer bloed lymfocyten (PBL) van gezonde donoren (Hoofdstuk 2). 
Optimale proliferatie van TCR- NK cellen werd verkregen door een combi-
natie van bestraalde allogene PBL en bestraalde Epstein Barr virus 
(EBV) getransformeerde lymfoblasto1de B-cellijnen (B-LCL) plus inter-
leukine 2 (IL2). Additie van 1 pg/ml van het lectine leucoagglutinine 
aan het kweekmedium induceerde een preferentiele uitgroei van TCR+ T 
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lymfocyten. Hoewel de proportie van TCR- NK cellen verlaagd was tot 5% 
of minder, werd een 2000-voudige vermeerdering verkregen van NK cellen 
tot aan dag 13. Zender leucoagglutinine werd een 1000-voudige vermeer-
dering verkregen van ongeveer 70% zuivere TCR- NK cellen tot aan dag 
13. 
De meerderheid van gekloneerde PBL hadden het immunofenotype 
TCRcx(3'" /CD4+. Nu en dan werden TCRyo+ klonen verkregen, die gedurende 
enige maanden in kweek gehouden konden worden. Ofschoon de levensduur 
van de meeste TCR- NK klonen beperkt is tot ongeveer 4 weken, hadden 
een aantal NK klonen een levensduur van 2-3 maanden. 
In Hoofdstuk 3 zijn de populatiesamenstelling en cytotoxische ken-
merken van PBL en tumor-infiltrerende lymfocyten (TIL) afkomstig van 
longtumorpatienten beschreven. TIL, maar niet PBL van longtumorpatien-
ten bevatten een lagere proportie NK cellen en vertonen een lagere NK-
en antilichaam-afhankelijke cytotoxische aktiviteit (ADCC) dan PBL van 
gezonde donoren. Na in vitro vermeerdering, gebruikmakend van de condi-
ties voor selectieve expansie zeals beschreven in Hoofdstuk 2, vertoon-
den de voor NK-cellen-verrijkte bulkkweken een hoge NK en ADCC aktivi-
teit. Klonering van PBL en TIL demonstreerde een verlaagde prolifera-
tieve capaciteit van TIL met cytotoxische aktiviteit. Echter de cyto-
toxische aktiviteit van de enkele groeiende klonen was gelijk aan die 
van gekloneerde PBL afkomstig van dezelfde patient of van normale dono-
ren. 
De vereisten voor aktivatie van het cytotoxisch mechanisme van 
lymfocyten subpopulaties via het aktivatiemolecuul CD2 werden onder-
zocht met behulp van bispecifieke Ab-heteroconjugaten (Hoofdstuk 4). 
Hiervoor werd een Ab-heteroconjugaat gebruikt bestaande uit een 
anti-CD2 mAb gekoppeld aan een anti-DNP mAb en TNP-behandelde tumorcel-
len. Op deze manier ontstaat een brugverbiri.ding tussen lymfocyt en 
tumorcel, wat tot aktivatie kan leiden van de lymfocyt. In tegenstel-
ling tot TCRcx(3'" CTL kan cytotoxische aktiviteit van TCR- NK celklonen 
en TCRyo+ CTL klonen worden ge1nduceerd via een anti-CD2 (anti-Tll.l) 
mAb-bevattend heteroconjugaat. Aktivatie van TCRyo+ CTL via CD2 is 
onafhankelijk van Ab-heteroconjugaatbinding aan CD16 (FcyRIII) omdat 
Ab-heteroconjugaten gemaakt van Fab fragmenten eenzelfde nivo van lysis 
induceerden. Bovendien werd de aktivatie van TCRyo+ CTL via CD2 niet 
geremd door anti-CD16 mAb. In TCR- NK cellen echter was dit wel het 
geval en werd bovendien een aanzienlijk lager nivo van lysis ge1ndu-
ceerd door Ab-heteroconjugaat gemaakt van Fab fragmenten. In TCR- NK 
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cellen is de inductie van cytotoxiciteit via C02 dus mede afhankelijk 
van een wisselwerking met CD16. 
Anti-CD3 mAb blokkeerde de anti-CD2 x anti-DNP Ab-heteroconjugaat 
ge1nduceerde cytotoxiciteit van TCRyo+ CTL, hetgeen wijst op een funk-
tionele relatie tussen C02 en CD3 op deze cellen. De konklusie is dat 
de vereisten voor inductie van cytotoxiciteit via C02 kwalitatief 
verschillend zijn voor TCR- NK cellen, TCR~~ en TCRyo+ CTL. 
De voornaamste aktivatieroute van T cellen verloopt via het TCR/CD3 
complex, dat funktioneel in verband staat met verscheidene helper mole-
culen. De rol van een van deze helper moleculen, LFA-1, in de 
CD3/TCR-gemedieerde lysis door TCR~ of TCRyo+ CTL is beschreven in 
Hoofdstuk 5. LFA-1 wordt onder andere geexpresseerd op de celmembraan 
van NK cellen en CTL en kan binden aan ICAM-1, een molecuul dat door 
een aantal verschillende celtypen geexpresseerd wordt. Daarom werden 
TNF-behandelde ICAM-1+ of ICAM-1- tumorcellijnen gebruikt als "target" 
cellen. Anti-CD3 en anti-CD18 (LFA-lSJ bevattende heteroconjugaten 
werden gebruikt om tumorcellen aan CTL te binden en om CTL te aktive-
ren. De ICAM-1- melanoom-afgeleide cellijn IgR39 bleek relatief resi-
stent tegen CD3-gemedieerde lysis door zowel TCR~ als TCRyo+ CTL, in 
vergelijking tot ICAM-1+ cellijnen. Induktie van ICAM-1 expressie op de 
membraan van IgR39 cellen door TNF maakte deze cellen gevoeliger voor 
CD3-gemedieerde lysis. Anti-ICAM-1 mAb remde deze verhoogde gevoelig-
heid voor lysis, aangevend dat de induktie van ICAM-1 expressie de 
kritieke faktor was in de TNF-ge1nduceerde toename in gevoeligheid voor 
lysis van IgR39 cellen. 
Het percentage gevormde conjugaten tussen CTL en ICAM-1- cellen was 
lager dan het percentage conjugaten tussen CTL en IC~-1+ cellen. Spon-
tane en anti-CD3 x anti-DNP Ab-heteroconjugaat ge1nduceerde conjugaat-
formatie alsmede CD3-gemedieerde lysis van ICAM-1- tumorcellen door CTL 
werden verhoogd door toevoeging van een anti-CD18 (LFA-1Sl bevattend 
heteroconjugaat. Dit anti-CD18 x anti-DNP Ab-heteroconjugaat bootst de 
LFA-1/ICAM-1 interaktie tussen CTL en tumorcel na, wat resulteert in 
toename van tumorcellysis. Anti-CD18 mAb niet gekoppeld aan een 
anti-DNP Ab remde de CD3-gemedieerde lysis van ICAM-1+ tumorcellen door 
CTL, alsmede de conjugaatformatie, door blokkering van de LFA-1/ICAM-1 
interaktie. Echter, anti-CD18 mAb remde ook de CD3-gemedieerde lysis 
van ICAM-1- tumorcellen door CTL, zonder de conjugaatformatie te be1n-
vloeden. Zelfs wanneer anti-CD18 mAb werd toegevoegd na conjugaatforma-
tie werd de lysis van zowel ICAM-1+ als ICAM-1- tumorcellen geremd. 
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Deze bevindingen suggereren dat de LFA-1/ICAM-1 interakties de 
CD3JTCR-gemedieerde lysis door CTL co-aktiveren. Dit vindt plaats door 
zowel een verhoogde CTL-tumorcel binding als door het leveren van een 
CD3-costimulatoir signaal nadat de conjugaatformatie heeft plaatsgevon-
den. 
TCR- NK cellen missen het CD3/TCR signaal transduktie mechanisme. 
Daarom rees de vraag of LFA-1/ICAM-1 interakties ook de gevoeligheid 
van tumorcellen voor MHC niet-gerestricteerde lysis door NK cellen 
beinvloeden (Hoofdstuk 6). Bovendien werd de rol van LFA-1/ICAM-1 
interakties onderzocht op de lysis van NK cellen die geaktiveerd zijn 
door een anti-CD16 mAb. Twee melanoom-afgeleide cellijnen met zwakke 
ICAM-1 expressie bleken relatief resistent tegen MHC niet-gerestric-
teerde en anti-CD16 mAb geinduceerde lysis door verse of gekloneerde 
TCR- NK cellen. De ICAM-1- melanoomcellen bleken ook relatief ongevoe-
lig voor MHC niet-gerestricteerde lysis door TCRy&+ klonen. TNF indu-
ceerde ICAM-1 expressie op ICAM-1- tumorcellen en verhoogde daardoor de 
gevoeligheid van deze cellen voor MHC niet-gerestricteerde en anti-CD16 
mAb geinduceerde lysis. Deze toegenomen gevoeligheid voor lysis werd 
weer verlaagd door anti-ICAM-1 mAb. Deze data laten zien dat LFA-1/ 
ICAM-1 interakties funktioneel en positief gecorreleerd zijn met gevoe-
ligheid voor MHC niet-gerestricteerde en CD16-gemedieerde lysis van 
tumorcellen. Anti-CD18 mAb remde zowel MHC niet-gerestricteerde lysis 
als anti-CD16 mAb ge1nduceerde lysis van ICAM-1- en ICAM-1+ tumorcel-
len. Zoals verwacht remde anti-CD18 mAb de conjugaatformatie met 
ICAM-1+ tumorcellen. Ondanks de remrning van lysis werd de conjugaatfor-
matie met ICAM-1- tumorcellen niet geremd. Dus LFA-1 speelt een ~­
conjugaat regulatoire rol in MHC niet-gerestricteerde lysis en anti-
CD16 ge1nduceerde lysis. 
In het laatste Hoofdstuk (Hoofdstuk 7) worden een aantal parameters 
bediscussieerd die de lysis van tumorcellen in vivo bepalen. 
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ADCC 
AK 
B-LCL 
CD 
CTL 
EBV 
E/T 
FACS 
FCS 
FITC 
HLA 
!CAM 
IFN 
Ig 
IL2 
LDCC 
LFA 
mAb 
MHC 
Mw 
NK 
PBL 
PE 
PHA 
LIST OF ABBREVIATIONS 
- antibody dependent cellular cytotoxicity 
- activated killer 
- lymphoblastoid B cell line 
- cluster designation 
- cytotoxic T lymphocyte(s) 
- Epstein Barr virus 
- effector/target 
- fluorescent activated cell sorter 
- fetal calf serum 
- fluorescein isothiocyanate 
- human leucocyte antigen 
- intercellular adhesion molecule 
- interferon 
- immunoglobulin 
- interleukin 2 
- lectin dependent cellular cytotoxicity 
- leucocyte function associated antigen 
- monoclonal antibody (ies) 
- major histocompatibility complex 
- molecular weight 
- natural killer 
- peripheral blood lymphocyte(s) 
- plating efficiency 
- phytohemagglutinin 
PMA - phorbol myristate acetate 
SPDP - N-succinimidyl-3-(2-pyridyldithiol propionate) 
SRBC - sheep red blood cell(s) 
TAA - tumor associated antigen 
TCR - T cell receptor 
TIL - tumor infiltrating lymphocyte(s) 
TNF - tumor necrosis factor 
TNP - trinitrobenzene sulfonate 
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